1
|
Milhem A, Anselme F, Da Costa A, Abbey S, Mansourati J, Bader H, Winum PF, Badenco N, Maury P, Dompnier A, Shah D, Johner N, Taieb J, Bertrand J, Tréguer F, Amelot M, Ingrand P, Allix-Béguec C. ATE Score Diagnostic Accuracy for Predicting the Absence of Intra-Atrial Thrombi Before AF Ablation. JACC Clin Electrophysiol 2023; 9:2550-2557. [PMID: 37804261 DOI: 10.1016/j.jacep.2023.08.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Revised: 08/14/2023] [Accepted: 08/20/2023] [Indexed: 10/09/2023]
Abstract
BACKGROUND In a preliminary study in patients hospitalized for catheter ablation of atrial fibrillation (AF), the atrial thrombus exclusion (ATE) score (stroke, hypertension, heart failure, and D-dimers >270 ng/mL) was developed to rule out the diagnosis of intra-atrial thrombus, with a negative predictive value (NPV) of 100%, and to avoid performing transesophageal echocardiography (TEE). OBJECTIVES The present study was designed to prospectively confirm the NPV of the ATE score in an independent population. METHODS Consecutive patients hospitalized for catheter ablation of AF or left atrial tachycardia (LAT) were prospectively enrolled in a multicenter study. D-dimer levels were measured within 48 hours before ablation. An ATE score of 0 was considered predictive of no thrombus. TEE was routinely performed at the beginning or just before the ablation procedure. The primary endpoint was the presence of atrial thrombus diagnosed by TEE. RESULTS The analysis included 3,072 patients (53.3% paroxysmal AF, 36.7% persistent AF, and 10% LAT). A thrombus was detected in 29 patients (0.94%; 95% CI: 0.63%-1.35%), all on appropriate anticoagulant therapy. An ATE score of 0 was observed in 818 patients (26.6%), and the sensitivity, specificity, positive predictive value, and NPV were 93.1%, 26.8%, 1.2%, and 99.8%, respectively. Follow-up of the 2 false negative patients revealed the persistence of chronic organized thrombi. CONCLUSIONS In patients hospitalized for catheter ablation of AF or LAT, the ATE score identifies a population at very low risk for atrial thrombus. In consultation with the patient, the cardiologist may consider not performing a preoperative TEE in case of an ATE score of 0.
Collapse
Affiliation(s)
- Antoine Milhem
- Department of Cardiology, CH la Rochelle, La Rochelle, France.
| | | | - Antoine Da Costa
- Department of Cardiology, CHU Saint-Etienne, Saint-Etienne, France
| | - Sélim Abbey
- Department of Cardiology, Nouvelles Cliniques Nantaises, Groupe Confluent, Nantes, France
| | | | | | | | - Nicolas Badenco
- Department of Cardiology, APHP, Hôpital Pitié Salpêtrière, Paris, France; Sorbonne Université, INSERM, UMRS 1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France
| | - Philippe Maury
- Department of Cardiology, CHU Toulouse, Toulouse, France
| | | | - Dipen Shah
- Department of Cardiology, University Hospital Geneva, Geneva, Switzerland
| | - Nicolas Johner
- Department of Cardiology, University Hospital Geneva, Geneva, Switzerland
| | - Jérôme Taieb
- Department of Cardiology, CH Pays d'Aix, Aix-en-Provence, France
| | - Julien Bertrand
- Department of Cardiology, CHR Metz-Thionville, Ars-Laquenexy, France
| | | | | | - Pierre Ingrand
- Epidemiology and Biostatistics, INSERM CIC 1402, Université de Poitiers, CHU Poitiers, Poitiers, France
| | | |
Collapse
|
2
|
Marrakchi S, Badenco N, Schumacher S, Bennour E, Livarek B, Gandjbakhch E, Hidden-Lucet F. Focus on malignant ventricular premature contractions. Ann Cardiol Angeiol (Paris) 2023; 72:101662. [PMID: 37742408 DOI: 10.1016/j.ancard.2023.101662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2023] [Revised: 08/21/2023] [Accepted: 08/21/2023] [Indexed: 09/26/2023]
Abstract
Premature ventricular contractions (PVCs) are common. Although often benign, they can also be associated with increased morbidity and mortality. The aim of this review was to assess the risk evaluation of PVCs in patients with or without structural heart disease and discuss the management of this arrhythmia. Reports published in English were searched in PubMed with the following search terms: premature ventricular contraction, ectopic ventricular beat, ventricular extrasystole, antiarrhythmic drugs, ablation, ventricular arrhythmia, ventricular tachycardia, ventricular fibrillation and torsade de pointe. This analysis suggests that all patients with frequent PVCs should be assessed for PVC burden, symptom status and the presence of structural heart disease. PVCs in patients with structurally normal hearts was once considered a benign phenomenon. Uncommonly, PVCs may provoke life-threatening arrhythmias. Ventricular fibrillation is the initial mode of malignant rapid ventricular arrhythmias (MRVAs). Patients with malignant PVC and PVC burden >10% are at increased risk of MRVA in case of myocardial infarction and heart failure. MRVA is the primary cause of sudden cardiac death in patients with and without structural heart disease. Therapeutic options include medical therapy and catheter ablation, the latter more effective and potentially curable, particularly in patients with left ventricular dysfunction. The timely recognition and effective treatment of malignant PVCs in symptomatic patients with underling cardiomyopathy are mandatory to initiate early therapies before the occurrence of adverse clinical outcomes and to improve the long-term prognosis.
Collapse
Affiliation(s)
- S Marrakchi
- Université de Sorbonne, AP-HP, Centre Hospitalo-universitaire Pitié-Salpêtrière, Institut de Cardiology, ICAN, Paris, France; Département de Cardiologie, Hospital André Mignot, Versailles, France; University El Manar, Tunis, Tunisie.
| | - N Badenco
- Université de Sorbonne, AP-HP, Centre Hospitalo-universitaire Pitié-Salpêtrière, Institut de Cardiology, ICAN, Paris, France
| | - S Schumacher
- Université de Sorbonne, AP-HP, Centre Hospitalo-universitaire Pitié-Salpêtrière, Institut de Cardiology, ICAN, Paris, France; Département de Cardiologie, Hospital André Mignot, Versailles, France
| | - E Bennour
- University El Manar, Tunis, Tunisie; Département de Cardiologie, Hospital Abderrahmane Mami Hospital, Tunis, Tunisie
| | - B Livarek
- Département de Cardiologie, Hospital André Mignot, Versailles, France
| | - E Gandjbakhch
- Université de Sorbonne, AP-HP, Centre Hospitalo-universitaire Pitié-Salpêtrière, Institut de Cardiology, ICAN, Paris, France
| | - F Hidden-Lucet
- Université de Sorbonne, AP-HP, Centre Hospitalo-universitaire Pitié-Salpêtrière, Institut de Cardiology, ICAN, Paris, France
| |
Collapse
|
3
|
Waldmann V, Marquié C, Bessière F, Perrot D, Anselme F, Badenco N, Barra S, Bertaux G, Blangy H, Bordachar P, Boveda S, Chauvin M, Clémenty N, Clerici G, Combes N, Defaye P, Deharo JC, Durand P, Duthoit G, Eschalier R, Fauchier L, Garcia R, Geoffroy O, Gitenay E, Gourraud JB, Guenancia C, Iserin L, Jacon P, Jesel-Morel L, Kerkouri F, Klug D, Koutbi L, Labombarda F, Ladouceur M, Laurent G, Leclercq C, Maille B, Maltret A, Massoulié G, Mondoly P, Ninni S, Ollitrault P, Pasquié JL, Pierre B, Pujadas P, Champ-Rigot L, Sacher F, Sadoul N, Schatz A, Winum P, Milliez PU, Probst V, Marijon E. Subcutaneous Implantable Cardioverter-Defibrillators in Patients With Congenital Heart Disease. J Am Coll Cardiol 2023; 82:590-599. [PMID: 37558371 DOI: 10.1016/j.jacc.2023.05.057] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Revised: 05/12/2023] [Accepted: 05/15/2023] [Indexed: 08/11/2023]
Abstract
BACKGROUND Very few data have been published on the use of subcutaneous implantable cardioverter-defibrillators (S-ICDs) in patients with congenital heart disease (CHD). OBJECTIVES The aim of this study was to analyze outcomes associated with S-ICDs in patients with CHD. METHODS This nationwide French cohort including all patients with an S-ICD was initiated in 2020 by the French Institute of Health and Medical Research. Characteristics at implantation and outcomes were analyzed in patients with CHD. RESULTS From October 12, 2012, to December 31, 2019, among 4,924 patients receiving an S-ICD implant in 150 centers, 101 (2.1%) had CHD. Tetralogy of Fallot, univentricular heart, and dextro-transposition of the great arteries represented almost one-half of the population. Patients with CHD were significantly younger (age 37.1 ± 15.4 years vs 50.1 ± 14.9 years; P < 0.001), more frequently female (37.6% vs 23.0%; P < 0.001), more likely to receive an S-ICD for secondary prevention (72.3% vs 35.9%; P < 0.001), and less likely to have severe systolic dysfunction of the systemic ventricle (28.1% vs 53.1%; P < 0.001). Over a mean follow-up period of 1.9 years, 16 (15.8%) patients with CHD received at least 1 appropriate shock, with all shocks successfully terminating the ventricular arrhythmia. The crude risk of appropriate S-ICD shock was twice as high in patients with CHD compared with non-CHD patients (annual incidences of 9.0% vs 4.4%; HR: 2.1; 95% CI: 1.3-3.4); however, this association was no longer significant after propensity matching (especially considering S-ICD indication, P = 0.12). The burden of all complications (HR: 1.2; 95% CI: 0.7-2.1; P = 0.4) and inappropriate shocks (HR: 0.9; 95% CI: 0.4-2.0; P = 0.9) was comparable in both groups. CONCLUSIONS In this nationwide study, patients with CHD represented 2% of all S-ICD implantations. Our findings emphasize the effectiveness and safety of S-ICD in this particularly high-risk population. (S-ICD French Cohort Study [HONEST]; NCT05302115).
Collapse
Affiliation(s)
- Victor Waldmann
- Université de Paris, INSERM, Paris Cardiovascular Research Centre, Paris, France; Adult Congenital Heart Disease Medico-Surgical Unit, European Georges Pompidou Hospital, Paris, France; Pediatric and Congenital Medico-Surgical Unit, Necker Hospital, Paris, France; Cardiac Electrophysiology Unit, European Georges Pompidou Hospital, Paris, France.
| | | | - Francis Bessière
- Université de Lyon, INSERM LabTau, Lyon, France; Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon, France
| | - David Perrot
- Université de Paris, INSERM, Paris Cardiovascular Research Centre, Paris, France; Cardiac Electrophysiology Unit, European Georges Pompidou Hospital, Paris, France
| | | | | | - Sergio Barra
- Université de Paris, INSERM, Paris Cardiovascular Research Centre, Paris, France; Cardiology Department, Hospital da Luz Arrábida, Vila Nova de Gaia, Portugal
| | | | | | | | | | - Michel Chauvin
- ICS HENA Strasbourg, Strasbourg, France; Clinique de l'Orangerie, Strasbourg, France
| | | | | | | | | | - Jean-Claude Deharo
- Assistance Publique-Hôpitaux de Marseille, Centre Hospitalier Universitaire La Timone, Service de Cardiologie, Marseille, France and Aix Marseille Université, C2VN, Marseille, France
| | - Philippe Durand
- Centre Médico-Chirurgical Arnault Tzanck, St Laurent du Var, France
| | | | - Romain Eschalier
- Cardiology Department, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France, and Université Clermont Auvergne, CHU Clermont-Ferrand, CNRS, SIGMA Clermont, Institut Pascal, F-63000 Clermont-Ferrand, France
| | | | - Rodrigue Garcia
- Cardiology Department, University Hospital of Poitiers, Poitiers, France; Centre d'Investigations Cliniques 1402, University Hospital of Poitiers, Poitiers, France
| | | | | | | | | | - Laurence Iserin
- Adult Congenital Heart Disease Medico-Surgical Unit, European Georges Pompidou Hospital, Paris, France
| | | | | | - Fawzi Kerkouri
- Université de Paris, INSERM, Paris Cardiovascular Research Centre, Paris, France; University Hospital of Brest, Brest, France
| | | | - Linda Koutbi
- Assistance Publique-Hôpitaux de Marseille, Centre Hospitalier Universitaire La Timone, Service de Cardiologie, Marseille, France and Aix Marseille Université, C2VN, Marseille, France
| | | | - Magalie Ladouceur
- Université de Paris, INSERM, Paris Cardiovascular Research Centre, Paris, France; Adult Congenital Heart Disease Medico-Surgical Unit, European Georges Pompidou Hospital, Paris, France
| | | | | | - Baptiste Maille
- Assistance Publique-Hôpitaux de Marseille, Centre Hospitalier Universitaire La Timone, Service de Cardiologie, Marseille, France and Aix Marseille Université, C2VN, Marseille, France
| | - Alice Maltret
- Hôpital Marie Lannelongue, Le Plessis Robinson, France
| | - Grégoire Massoulié
- Cardiology Department, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France, and Université Clermont Auvergne, CHU Clermont-Ferrand, CNRS, SIGMA Clermont, Institut Pascal, F-63000 Clermont-Ferrand, France
| | | | | | | | - Jean-Luc Pasquié
- PhyMedExp, Université de Montpellier, INSERM, CNRS, CHRU de Montpellier, France
| | | | | | | | | | | | | | | | | | | | - Eloi Marijon
- Université de Paris, INSERM, Paris Cardiovascular Research Centre, Paris, France; Pediatric and Congenital Medico-Surgical Unit, Necker Hospital, Paris, France
| |
Collapse
|
4
|
Benali K, Barré V, Hermida A, Galand V, Milhem A, Philibert S, Boveda S, Bars C, Anselme F, Maille B, André C, Behaghel A, Moubarak G, Clémenty N, Da Costa A, Arnaud M, Venier S, Sebag F, Jésel-Morel L, Sagnard A, Champ-Rigot L, Dang D, Guy-Moyat B, Abbey S, Garcia R, Césari O, Badenco N, Lepillier A, Ninni S, Boulé S, Maury P, Algalarrondo V, Bakouboula B, Mansourati J, Lesaffre F, Lagrange P, Bouzeman A, Muresan L, Bacquelin R, Bortone A, Bun SS, Pavin D, Macle L, Martins RP. Recurrences of Atrial Fibrillation Despite Durable Pulmonary Vein Isolation: The PARTY-PVI Study. Circ Arrhythm Electrophysiol 2023; 16:e011354. [PMID: 36802906 DOI: 10.1161/circep.122.011354] [Citation(s) in RCA: 12] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
BACKGROUND Recurrences of atrial fibrillation (AF) after pulmonary vein isolation (PVI) are mainly due to pulmonary vein reconnection. However, a growing number of patients have AF recurrences despite durable PVI. The optimal ablative strategy for these patients is unknown. We analyzed the impact of current ablation strategies in a large multicenter study. METHODS Patients undergoing a redo ablation for AF and presenting durable PVI were included. The freedom from atrial arrhythmia after pulmonary vein-based, linear-based, electrogram-based, and trigger-based ablation strategies were compared. RESULTS Between 2010 and 2020, 367 patients (67% men, 63±10 years, 44% paroxysmal) underwent a redo ablation for AF recurrences despite durable PVI at 39 centers. After durable PVI was confirmed, linear-based ablation was performed in 219 (60%) patients, electrogram-based ablation in 168 (45%) patients, trigger-based ablation in 101 (27%) patients, and pulmonary vein-based ablation in 56 (15%) patients. Seven patients (2%) did not undergo any additional ablation during the redo procedure. After 22±19 months of follow-up, 122 (33%) and 159 (43%) patients had a recurrence of atrial arrhythmia at 12 and 24 months, respectively. No significant difference in arrhythmia-free survival was observed between the different ablation strategies. Left atrial dilatation was the only independent factor associated with arrhythmia-free survival (HR, 1.59 [95% CI, 1.13-2.23]; P=0.006). CONCLUSIONS In patients with recurrent AF despite durable PVI, no ablation strategy used alone or in combination during the redo procedure appears to be superior in improving arrhythmia-free survival. Left atrial size is a significant predictor of ablation outcome in this population.
Collapse
Affiliation(s)
- Karim Benali
- CHU Saint Etienne, University of Rennes, INSERM, LTSI -UMR 1099, Rennes (K.B.)
| | - Valentin Barré
- University of Rennes, CHU Rennes, INSERM, LTSI-UMR 1099, Rennes (V.B., V.G., D.P., R.P.M.)
| | | | - Vincent Galand
- University of Rennes, CHU Rennes, INSERM, LTSI-UMR 1099, Rennes (V.B., V.G., D.P., R.P.M.)
| | | | | | - Serge Boveda
- Cardiology-Heart Rhythm Management Department, Clinique Pasteur, Toulouse (S.B.)
| | | | | | | | | | | | | | | | | | | | | | - Frédéric Sebag
- Rythmologie, Institut Mutualiste Montsouris, Paris (F.S.)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Babé Bakouboula
- Institut Cardiovasculaire de Strasbourg, Clinique RHENA (B.B.)
| | | | | | | | | | | | | | | | | | - Dominique Pavin
- University of Rennes, CHU Rennes, INSERM, LTSI-UMR 1099, Rennes (V.B., V.G., D.P., R.P.M.)
| | - Laurent Macle
- Department of Medicine, Electrophysiology Service at the Montreal Heart Institute, Canada (L.M.)
| | - Raphaël P Martins
- University of Rennes, CHU Rennes, INSERM, LTSI-UMR 1099, Rennes (V.B., V.G., D.P., R.P.M.)
| |
Collapse
|
5
|
Delasnerie H, Gandjbakhch E, Sauve R, Beneyto M, Domain G, Voglimacci-Stephanopoli Q, Mandel F, Badenco N, Waintraub X, Mondoly P, Fressart V, Rollin A, Maury P. Correlations Between Endocardial Voltage Mapping, Diagnosis, and Genetics in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy. Am J Cardiol 2023; 190:113-120. [PMID: 36621286 DOI: 10.1016/j.amjcard.2022.11.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/27/2022] [Revised: 11/01/2022] [Accepted: 11/19/2022] [Indexed: 01/09/2023]
Abstract
The relations between endocardial voltage mapping and the genetic background of patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) have not been investigated so far. A total of 97 patients with proved or suspected ARVC who underwent 3-dimensional endocardial mapping and genetic testing have been retrospectively included. Presence, localization, and size of scar areas were correlated to ARVC diagnosis and the presence of a pathogenic variant. A total of 78 patients (80%) presented with some bipolar or unipolar scar on endocardial voltage mapping, whereas 43 carried pathogenic variants (44%). Significant associations were observed between presence of endocardial scars on voltage mapping and previous or inducible ventricular tachycardia, right ventricular function and dimensions, or electrocardiogram features of ARVC. A total of 60 of the 78 patients (77%) with an endocardial scar fulfilled the criteria for a definitive arrhythmogenic right ventricular dysplasia diagnosis versus 8 of 19 patients (42%) without scar (p = 0.003). Patients with a definitive diagnosis of ARVC had more scars from any location and the scars were larger in patients with ARVC. In the 68 patients with a definitive diagnosis of ARVC, the presence of any endocardial scar was similar whether an ARVC-causal mutation was present or not. Only scar extent was significantly greater in patients with pathogenic variants. There was no difference in the presence and characteristics of scars in PKP2 mutated versus other mutated patients. The 3-dimensional endocardial mapping could have an important role for refining ARVC diagnosis and may be able to detect minor forms with otherwise insufficient criteria for diagnosis. The trend for larger scar extent were observed in mutated patients, without any difference according to the mutated genes.
Collapse
Affiliation(s)
- Hubert Delasnerie
- Department of Cardiology, Cardiology University Hospital Toulouse, Toulouse, France
| | - Estelle Gandjbakhch
- Department of Cardiology, Sorbonne Universités, AP-HP, Heart Institute, La Pitié-Salpêtrière University Hospital, Paris, France
| | - Romain Sauve
- Biosense, Johnson & Johnson, Issy-les-Moulineaux, France
| | - Maxime Beneyto
- Department of Cardiology, Cardiology University Hospital Toulouse, Toulouse, France
| | - Guillaume Domain
- Department of Cardiology, Cardiology University Hospital Toulouse, Toulouse, France
| | | | - Franck Mandel
- Department of Cardiology, Cardiology University Hospital Toulouse, Toulouse, France
| | - Nicolas Badenco
- Department of Cardiology, Sorbonne Universités, AP-HP, Heart Institute, La Pitié-Salpêtrière University Hospital, Paris, France
| | - Xavier Waintraub
- Department of Cardiology, Sorbonne Universités, AP-HP, Heart Institute, La Pitié-Salpêtrière University Hospital, Paris, France
| | - Pierre Mondoly
- Department of Cardiology, Cardiology University Hospital Toulouse, Toulouse, France
| | - Véronique Fressart
- Service de Biochimie Métabolique, La Pitié-Salpêtrière University Hospital, Paris, France
| | - Anne Rollin
- Department of Cardiology, Cardiology University Hospital Toulouse, Toulouse, France
| | - Philippe Maury
- Department of Cardiology, Cardiology University Hospital Toulouse, Toulouse, France; I2MC, Inserm UMR 1297, Toulouse, France.
| |
Collapse
|
6
|
Laredo M, Tovia-Brodie O, Milman A, Michowitz Y, Roudijk RW, Peretto G, Badenco N, Te Riele ASJM, Sala S, Duthoit G, Arbelo E, Ninni S, Gasperetti A, van Tintelen JP, Paglino G, Waintraub X, Andorin A, Peichl P, Bosman LP, Calo L, Giustetto C, Radinovic A, Jorda P, Casado-Arroyo R, Zorio E, Bermúdez-Jiménez FJ, Behr ER, Havranek S, Tfelt-Hansen J, Sacher F, Hermida JS, Nof E, Casella M, Kautzner J, Lacroix D, Brugada J, Duru F, Bella PD, Gandjbakhch E, Hauer R, Belhassen B. Electrocardiographic findings in patients with arrhythmogenic cardiomyopathy and right bundle branch block ventricular tachycardia. Europace 2023; 25:1025-1034. [PMID: 36635857 PMCID: PMC10062349 DOI: 10.1093/europace/euac267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2022] [Accepted: 12/02/2022] [Indexed: 01/14/2023] Open
Abstract
AIMS Little is known about patients with right bundle branch block (RBBB)-ventricular tachycardia (VT) and arrhythmogenic cardiomyopathy (ACM). Our aims were: (i) to describe electrocardiogram (ECG) characteristics of sinus rhythm (SR) and VT; (ii) to correlate SR with RBBB-VT ECGs; and (iii) to compare VT ECGs with electro-anatomic mapping (EAM) data. METHODS AND RESULTS From the European Survey on ACM, 70 patients with spontaneous RBBB-VT were included. Putative left ventricular (LV) sites of origin (SOOs) were estimated with a VT-axis-derived methodology and confirmed by EAM data when available. Overall, 49 (70%) patients met definite Task Force Criteria. Low QRS voltage predominated in lateral leads (n = 37, 55%), but QRS fragmentation was more frequent in inferior leads (n = 15, 23%). T-wave inversion (TWI) was equally frequent in inferior (n = 28, 42%) and lateral (n = 27, 40%) leads. TWI in inferior leads was associated with reduced LV ejection fraction (LVEF; 46 ± 10 vs. 53 ± 8, P = 0.02). Regarding SOOs, the inferior wall harboured 31 (46%) SOOs, followed by the lateral wall (n = 17, 25%), the anterior wall (n = 15, 22%), and the septum (n = 4, 6%). EAM data were available for 16 patients and showed good concordance with the putative SOOs. In all patients with superior-axis RBBB-VT who underwent endo-epicardial VT activation mapping, VT originated from the LV. CONCLUSIONS In patients with ACM and RBBB-VT, RBBB-VTs originated mainly from the inferior and lateral LV walls. SR depolarization and repolarization abnormalities were frequent and associated with underlying variants.
Collapse
Affiliation(s)
- Mikael Laredo
- Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, and Sorbonne Université, 47-83 boulevard de l'Hôpital, 75013, Paris, France
| | - Oholi Tovia-Brodie
- Department of Cardiology, Jesselson Integrated Heart Center, Shaare Zedek Medical Center, Jerusalem, Israel
| | - Anat Milman
- Leviev Heart Institute, Sheba Medical Center, Tel-Hashomer and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Yoav Michowitz
- Department of Cardiology, Jesselson Integrated Heart Center, Shaare Zedek Medical Center, Jerusalem, Israel
| | - Rob W Roudijk
- Netherlands Heart Institute, Utrecht, The Netherlands
| | | | - Nicolas Badenco
- Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, and Sorbonne Université, 47-83 boulevard de l'Hôpital, 75013, Paris, France
| | - Anneline S J M Te Riele
- Netherlands Heart Institute, Utrecht, The Netherlands.,Department of Cardiology, University Medical Center, Utrecht, The Netherlands
| | - Simone Sala
- IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Guillaume Duthoit
- Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, and Sorbonne Université, 47-83 boulevard de l'Hôpital, 75013, Paris, France
| | - Elena Arbelo
- Arrhythmia Section, Cardiology Department, Hospital Clínic, Universitat de Barcelona, and IDIBAPS, Institut d'Investigació August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Sandro Ninni
- Université de Lille et Institut Cœur-Poumon, CHRU Lille, Lille, France
| | - Alessio Gasperetti
- Department of Cardiology, University Heart Center Zurich, Zurich, Switzerland
| | - J Peter van Tintelen
- Netherlands Heart Institute, Utrecht, The Netherlands.,Department of Genetics, University Medical Center, Utrecht, The Netherlands
| | | | - Xavier Waintraub
- Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, and Sorbonne Université, 47-83 boulevard de l'Hôpital, 75013, Paris, France
| | | | - Petr Peichl
- Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
| | - Laurens P Bosman
- Netherlands Heart Institute, Utrecht, The Netherlands.,Department of Cardiology, University Medical Center, Utrecht, The Netherlands
| | - Leonardo Calo
- Division of Cardiology, Policlinico Casilino, Roma, Italy
| | - Carla Giustetto
- Division of Cardiology, University of Torino, Department of Medical Sciences, Città della Salute e della Scienza Hospital, Torino, Italy
| | | | - Paloma Jorda
- Arrhythmia Section, Cardiology Department, Hospital Clínic, Universitat de Barcelona, and IDIBAPS, Institut d'Investigació August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Ruben Casado-Arroyo
- Department of Cardiology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | - Esther Zorio
- Cardiology Department at Hospital Universitario y Politecnico La Fe and Research Group on Inherited Heart Diseases, Sudden Death and Mechanisms of Disease (CaFaMuSMe) from the Instituto de Investigación Sanitaria (IIS) La Fe, Valencia, Spain.,Center for Biomedical Network Research on Cardiovascular Diseases (CIBERCV), Madrid, Spain
| | | | - Elijah R Behr
- Cardiovascular Sciences and Cardiology Clinical Academic Group St. George's University Hospitals NHS Foundation Trust, London, UK
| | - Stepan Havranek
- Second Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
| | - Jacob Tfelt-Hansen
- The Department of Cardiology, The Heart Centre, Copenhagen University Hospital, Rigshospitalet, and Section of genetics, Department of Forensic Medicine, Faculty of Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Frederic Sacher
- Hôpital Cardiologique du Haut-Lévêque & Université Bordeaux, LIRYC Institute, Bordeaux, France
| | | | - Eyal Nof
- Leviev Heart Institute, Sheba Medical Center, Tel-Hashomer and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Michela Casella
- Cardiology and Arrhythmology Clinic, Department of Clinical, Special and Dental Sciences, Marche Polytechnic University, Ancona, Italy
| | - Josef Kautzner
- Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
| | - Dominique Lacroix
- Université de Lille et Institut Cœur-Poumon, CHRU Lille, Lille, France
| | - Josep Brugada
- Arrhythmia Section, Cardiology Department, Hospital Clínic, Universitat de Barcelona, and IDIBAPS, Institut d'Investigació August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Firat Duru
- Department of Cardiology, University Heart Center Zurich, Zurich, Switzerland
| | | | - Estelle Gandjbakhch
- Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, and Sorbonne Université, 47-83 boulevard de l'Hôpital, 75013, Paris, France
| | - Richard Hauer
- Netherlands Heart Institute, Utrecht, The Netherlands.,Department of Cardiology, University Medical Center, Utrecht, The Netherlands
| | - Bernard Belhassen
- Heart Institute, Hadassah University Hospital, Jerusalem and Sackler School of Medicine, Tel-Aviv University, Kyriat Hadassah, PO Box 12000, 91120, Jerusalem, Israel
| |
Collapse
|
7
|
Petruescu L, Lebreton G, Coutance G, Maupain C, Fressart V, Badenco N, Waintraub X, Duthoit G, Laredo M, Himbert C, Hidden-Lucet F, Leprince P, Varnous S, Gandjbakhch E. Clinical course of arrhythmogenic right ventricular cardiomyopathy with end-stage heart failure and outcome after heart transplantation. Arch Cardiovasc Dis 2023; 116:9-17. [PMID: 36609000 DOI: 10.1016/j.acvd.2022.10.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Revised: 10/04/2022] [Accepted: 10/06/2022] [Indexed: 12/13/2022]
Abstract
BACKGROUND Few data exist on the characteristics and outcomes of patients with arrhythmogenic right ventricular cardiomyopathy and advanced heart failure who undergo heart transplantation. AIM To explore the pretransplant course and outcomes of patients with arrhythmogenic right ventricular cardiomyopathy after heart transplantation. METHODS This observational retrospective monocentric study included all consecutive patients with arrhythmogenic right ventricular cardiomyopathy who underwent heart transplantation during a 13-year period (2006-2019) at Pitié-Salpêtrière University Hospital (Paris). RESULTS A total of 23 patients with arrhythmogenic right ventricular cardiomyopathy underwent heart transplantation between 2006 and 2019. The median time from diagnosis to heart transplantation was 9 years, and the median age at transplantation was 50 years. At diagnosis, half of the patients had left ventricular dysfunction, 59% had extensive T-wave inversion and 43% had a history of sustained ventricular tachycardia. Only five patients were involved in intensive sport activity. Indications for heart transplantation were end-stage biventricular dysfunction in 13 patients, end-stage right ventricular heart failure in seven and electrical storm in three. Only three patients had pulmonary hypertension, and half of the patients had atrial arrhythmias. The survival rate 1 year after heart transplantation was 74% (95% confidence interval 53-88%). Eight patients experienced primary graft dysfunction needing extracorporeal membrane oxygenation. CONCLUSIONS Patients with arrhythmogenic right ventricular cardiomyopathy who eventually needed heart transplantation mostly exhibited extended disease with biventricular dysfunction at diagnosis. Intensive sport activity did not seem to be a major determinant. Advanced heart failure usually occurred late in the course of the disease. Primary graft dysfunction after heart transplantation was frequent, and should be anticipated. Additional data are needed to identify the optimal timing for heart transplantation and predictors of end-stage heart failure in patients with arrhythmogenic right ventricular cardiomyopathy.
Collapse
Affiliation(s)
- Laura Petruescu
- APHP, Département de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtrière, Fondation ICAN, 75013 Paris, France; Diagnosis and Therapeutic Center, Hôpital Hôtel-Dieu, AP-HP, université de Paris, 75004 Paris, France
| | - Guillaume Lebreton
- Sorbonne Université, 75013, Paris, France; Diagnosis and Therapeutic Center, Hôpital Hôtel-Dieu, AP-HP, université de Paris, 75004 Paris, France
| | - Guillaume Coutance
- Sorbonne Université, 75013, Paris, France; Diagnosis and Therapeutic Center, Hôpital Hôtel-Dieu, AP-HP, université de Paris, 75004 Paris, France
| | - Carole Maupain
- APHP, Département de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtrière, Fondation ICAN, 75013 Paris, France
| | - Véronique Fressart
- APHP, Service de Biochimie Métabolique, UF cardiogénétique et myogénétique moléculaire et cellulaire, centre hospitalier universitaire Pitié-Salpêtrière, 75013 Paris, France
| | - Nicolas Badenco
- APHP, Département de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtrière, Fondation ICAN, 75013 Paris, France
| | - Xavier Waintraub
- APHP, Département de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtrière, Fondation ICAN, 75013 Paris, France
| | - Guillaume Duthoit
- APHP, Département de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtrière, Fondation ICAN, 75013 Paris, France
| | - Mikael Laredo
- APHP, Département de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtrière, Fondation ICAN, 75013 Paris, France
| | - Caroline Himbert
- APHP, Département de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtrière, Fondation ICAN, 75013 Paris, France
| | - Francoise Hidden-Lucet
- APHP, Département de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtrière, Fondation ICAN, 75013 Paris, France
| | - Pascal Leprince
- Sorbonne Université, 75013, Paris, France; APHP, Département de Chirurgie Cardiaque, Centre Hospitalier Universitaire Pitié-Salpêtrière, 75013 Paris, France
| | - Shaida Varnous
- APHP, Département de Chirurgie Cardiaque, Centre Hospitalier Universitaire Pitié-Salpêtrière, 75013 Paris, France
| | - Estelle Gandjbakhch
- APHP, Département de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtrière, Fondation ICAN, 75013 Paris, France; Sorbonne Université, 75013, Paris, France.
| |
Collapse
|
8
|
Schiavone M, Gasperetti A, Laredo M, Breitenstein A, Vogler J, Palmisano P, Gulletta S, Pignalberi C, Lavalle C, Pisanò E, Ricciardi D, Curnis A, Dello Russo A, Tondo C, Badenco N, Di Biase L, Kuschyk J, Biffi M, Tilz R, Forleo GB, Arosio R, Ruggiero D, Viecca M, Ziacchi M, Diemberger I, Angeletti A, Fierro N, Della Bella P, Mitacchione G, Compagnucci P, Casella M, Santini L, Piro A, Picarelli F, Bressi E, Calò L, Montemerlo E, Rovaris G, De Bonis S, Bisignani A, Bisignani G, Russo G, Guarracini F, Vitali F, Bertini M, Fink T, Fastenrath F, Kaiser L, Hakmi S, Waintraub X, Gandjbakhch E, Saguner A. Inappropriate Shock Rates and Long-Term Complications due to Subcutaneous Implantable Cardioverter Defibrillators in Patients With and Without Heart Failure: Results From a Multicenter, International Registry. Circ Arrhythm Electrophysiol 2023; 16:e011404. [PMID: 36595631 DOI: 10.1161/circep.122.011404] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Affiliation(s)
- Marco Schiavone
- Luigi Sacco University Hospital, Milan (M.S., A.G., G.B.F.).,Department of Systems Medicine, University of Rome Tor Vergata, Italy (M.S.)
| | - Alessio Gasperetti
- Luigi Sacco University Hospital, Milan (M.S., A.G., G.B.F.).,Department of Cardiology, Johns Hopkins University, Baltimore, MD (A.G., N.B.)
| | - Mikael Laredo
- APHP, Hôpital Pitié Salpêtrière, Paris, France (M.L.)
| | | | - Julia Vogler
- Department of Elctrophysiology, Herzzentrum Lubeck, Germany (J.V., R.T.)
| | - Pietro Palmisano
- Cardiology Unit, "Card. G. Panico" Hospital, Tricase, Italy (P.P.)
| | - Simone Gulletta
- Arrhythmology & Electrophysiology Unit, San Raffaele Hospital, IRCCS, Milan (S.G.)
| | | | | | - Ennio Pisanò
- U.O.S.V.D. Cardiac Electrophysiology - "V. Fazzi" Hospital, Lecce (E.P.)
| | | | | | - Antonio Dello Russo
- Cardiology and Arrhythmology Clinic, University Hospital "Umberto I-Salesi-Lancisi," Ancona (A.D.R.)
| | - Claudio Tondo
- Heart Rhythm Centre, Monzino Cardiology Centre, IRCCS, Milan, Italy (C.T.)
| | - Nicolas Badenco
- Department of Cardiology, Johns Hopkins University, Baltimore, MD (A.G., N.B.)
| | - Luigi Di Biase
- Cardiac Arrhythmia Center, Division of Cardiology at Montefiore-Einstein Center, Bronx, NY (L.D.B.)
| | - Jürgen Kuschyk
- Cardiology Unit, University Medical Center Mannheim, Germany (J.K.)
| | - Mauro Biffi
- Cardiology, IRCCS, Department of Experimental, Diagnostic & Specialty Medicine, Sant'Orsola Hospital, University of Bologna, Bologna, Italy (M.B.)
| | - Roland Tilz
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Partner Site Hamburg/Kiel/Lübeck, Lübeck, Germany (R.T.)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Ben Kilani M, Jacon P, Badenco N, Marquie C, Ollitrault P, Behar N, Khattar P, Carabelli A, Venier S, Defaye P. Pre-implant predictors of inappropriate shocks with the third-generation subcutaneous implantable cardioverter defibrillator. Europace 2022; 24:1952-1959. [PMID: 36002951 DOI: 10.1093/europace/euac134] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Accepted: 06/30/2022] [Indexed: 12/14/2022] Open
Abstract
AIMS Despite recent improvements, inappropriate shocks emitted by implanted subcutaneous implantable cardioverter defibrillators (S-ICDs) remain a challenge in 'real-life' practice. We aimed to study the pre-implant factors associated with inappropriate shocks for the latest generation of S-ICDs. METHODS AND RESULTS Three-hundred patients implanted with the third-generation S-ICD system for primary or secondary prevention between January 2017 and March 2020 were included in this multicentre retrospective observational study. A follow-up of at least 6 months and pre-implant screening procedure data were mandatory for inclusion. During a mean follow-up of 22.8 (±11.4) months, 37 patients (12.3%) received appropriate S-ICD shock therapy, whereas 26 patients (8.7%) experienced inappropriate shocks (incidence 4.9 per 100 patient years). The total number of inappropriate shock episodes was 48, with nine patients experiencing multiple episodes. The causes of inappropriate shocks included supraventricular arrhythmias (34.6%) and cardiac (30.7%) or extra-cardiac noise (38.4%) oversensing. Using multivariate analysis, we explored the independent factors associated with inappropriate shocks. These were the availability of less than three sensing vectors during pre-implant screening [hazard ratio (HR), 0.33; 95% confidence interval (CI), 0.11-0.93; P = 0.035], low QRS/T wave ratio in Lead I (for a threshold <3; HR, 4.79; 95% CI, 2.00-11.49; P < 0.001), history of supraventricular tachycardia (HR, 8.67; 95% CI, 2.80-26.7; P < 0.001), and being overweight (body mass index > 25; HR, 2.66; 95% CI, 1.10-6.45; P = 0.03). CONCLUSION Automatic pre-implant screening data are a useful quantitative predictor of inappropriate shocks. Electrocardiogram features should be taken into consideration along with other clinical factors to identify patients at high risk of inappropriate shocks.
Collapse
Affiliation(s)
- Mouna Ben Kilani
- Department of Cardiology, Grenoble-Alpes University Hospital, 38043 Grenoble, France
| | - Peggy Jacon
- Department of Cardiology, Grenoble-Alpes University Hospital, 38043 Grenoble, France
| | - Nicolas Badenco
- Department of Cardiology, Pitie Salpetriere APHP University Hospital, Paris, France
| | | | | | - Nathalie Behar
- Department of Cardiology, Rennes University Hospital, Rennes, France
| | - Pierre Khattar
- Department of Cardiology, Scorff Hospital-Hospital Centre of Bretagne Sud, Lorient, France
| | - Adrien Carabelli
- Department of Cardiology, Grenoble-Alpes University Hospital, 38043 Grenoble, France
| | - Sandrine Venier
- Department of Cardiology, Grenoble-Alpes University Hospital, 38043 Grenoble, France
| | - Pascal Defaye
- Department of Cardiology, Grenoble-Alpes University Hospital, 38043 Grenoble, France
| |
Collapse
|
10
|
Gasperetti A, Schiavone M, Vogler J, Laredo M, Fastenrath F, Palmisano P, Ziacchi M, Angeletti A, Mitacchione G, Kaiser L, Compagnucci P, Breitenstein A, Arosio R, Vitali F, De Bonis S, Picarelli F, Casella M, Santini L, Pignalberi C, Lavalle C, Pisanò E, Ricciardi D, Calò L, Curnis A, Bertini M, Gulletta S, Dello Russo A, Badenco N, Tondo C, Kuschyk J, Tilz R, Forleo GB, Biffi M. The need for a subsequent transvenous system in patients implanted with subcutaneous implantable cardioverter-defibrillator. Heart Rhythm 2022; 19:1958-1964. [PMID: 35781042 DOI: 10.1016/j.hrthm.2022.06.030] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/06/2022] [Revised: 06/21/2022] [Accepted: 06/24/2022] [Indexed: 12/14/2022]
Abstract
BACKGROUND The absence of pacing capabilities may reduce the appeal of subcutaneous implantable cardioverter-defibrillator (S-ICD) devices for patients at risk for conduction disorders or with antitachycardia pacing (ATP)/cardiac resynchronization (CRT) requirements. Reports of rates of S-ICD to transvenous implantable cardioverter-defibrillator (TV-ICD) system switch in real-world scenarios are limited. OBJECTIVE The purpose of this study was to investigate the need for a subsequent transvenous (TV) device in patients implanted with an S-ICD and its predictors. METHODS All patients implanted with an S-ICD were enrolled from the multicenter, real-world iSUSI (International SUbcutaneouS Implantable cardioverter defibrillator) Registry. The need for a TV device and its clinical reason, and appropriate and inappropriate device therapies were assessed. Logistic regression with Firth penalization was used to assess the association between baseline and procedural characteristics and the overall need for a subsequent TV device. RESULTS A total of 1509 patients were enrolled (age 50.8 ± 15.8 years; 76.9% male; 32.0% ischemic; left ventricular ejection fraction 38% [30%-60%]). Over 26.5 [13.4-42.9] months, 155 (10.3%) and 144 (9.3%) patients experienced appropriate and inappropriate device therapies, respectively. Forty-one patients (2.7%) required a TV device (13 bradycardia; 10 need for CRT; 10 inappropriate shocks). Body mass index (BMI) >30 kg/m2 and chronic kidney disease (CKD) were associated with need for a TV device (odds ratio [OR] 2.57 [1.37-4.81], P = .003; and OR 2.67 [1.29-5.54], P = .008, respectively). CONCLUSION A low rate (2.7%) of conversion from S-ICD to a TV device was observed at follow-up, with need for antibradycardia pacing, ATP, or CRT being the main reasons. BMI >30 kg/m2 and CKD predicted all-cause need for a TV device.
Collapse
Affiliation(s)
- Alessio Gasperetti
- Cardiology Unit, Luigi Sacco University Hospital, Milan, Italy; Università degli Studi di Milano, Milan, Italy; Johns Hopkins University, Baltimore, Maryland; Department of Biomedical Sciences and Public Health, Marche Polytechnic University, Ancona, Italy.
| | | | - Julia Vogler
- Department of Rhythmology, Herzzentrum Lubeck, Lubeck, Germany
| | | | - Fabian Fastenrath
- Cardiology Unit, University Medical Centre Mannheim, Manheim, Germany
| | | | - Matteo Ziacchi
- Cardiology Unit, IRCCS, Department of Experimental, Diagnostic and Specialty Medicine, Sant'Orsola Hospital, University of Bologna, Bologna, Italy
| | - Andrea Angeletti
- Cardiology Unit, IRCCS, Department of Experimental, Diagnostic and Specialty Medicine, Sant'Orsola Hospital, University of Bologna, Bologna, Italy
| | - Gianfranco Mitacchione
- Cardiology Unit, Luigi Sacco University Hospital, Milan, Italy; Cardiology Unit, Spedali Civili Brescia, Brescia, Italy
| | | | - Paolo Compagnucci
- Department of Biomedical Sciences and Public Health, Marche Polytechnic University, Ancona, Italy; Cardiology and Arrhythmology Clinic, University Hospital Ospedali Riuniti, Ancona, Italy
| | | | | | - Francesco Vitali
- Cardiological Center, S. Anna University Hospital, Ferrara, Italy
| | - Silvana De Bonis
- Department of Cardiology, Castrovillari Hospital, Cosenza, Italy
| | | | - Michela Casella
- Cardiology and Arrhythmology Clinic, University Hospital Ospedali Riuniti, Ancona, Italy
| | - Luca Santini
- Cardiology Unit, Ospedale G.B. Grassi, Ostia, Italy
| | | | | | - Ennio Pisanò
- Cardiac Electrophysiology Unit, Vito Fazzi Hospital, Lecce, Italy
| | | | | | | | - Matteo Bertini
- Cardiological Center, S. Anna University Hospital, Ferrara, Italy
| | - Simone Gulletta
- Arrhythmology and Electrophysiology Unit, San Raffaele Hospital, IRCCS, Milan, Italy
| | - Antonio Dello Russo
- Department of Biomedical Sciences and Public Health, Marche Polytechnic University, Ancona, Italy; Cardiology and Arrhythmology Clinic, University Hospital Ospedali Riuniti, Ancona, Italy
| | | | - Claudio Tondo
- Heart Rhythm Center, Monzino Cardiology Center, IRCCS, Milan, Italy
| | - Jürgen Kuschyk
- Cardiology Unit, University Medical Centre Mannheim, Manheim, Germany
| | - Roland Tilz
- Department of Rhythmology, Herzzentrum Lubeck, Lubeck, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Lübeck, Germany
| | | | - Mauro Biffi
- Cardiology Unit, IRCCS, Department of Experimental, Diagnostic and Specialty Medicine, Sant'Orsola Hospital, University of Bologna, Bologna, Italy
| |
Collapse
|
11
|
Proietti M, Romiti GF, Vitolo M, Harrison SL, Lane DA, Fauchier L, Marin F, Näbauer M, Potpara TS, Dan GA, Maggioni AP, Cesari M, Boriani G, Lip GYH, Ekmekçiu U, Paparisto V, Tase M, Gjergo H, Dragoti J, Goda A, Ciutea M, Ahadi N, el Husseini Z, Raepers M, Leroy J, Haushan P, Jourdan A, Lepiece C, Desteghe L, Vijgen J, Koopman P, Van Genechten G, Heidbuchel H, Boussy T, De Coninck M, Van Eeckhoutte H, Bouckaert N, Friart A, Boreux J, Arend C, Evrard P, Stefan L, Hoffer E, Herzet J, Massoz M, Celentano C, Sprynger M, Pierard L, Melon P, Van Hauwaert B, Kuppens C, Faes D, Van Lier D, Van Dorpe A, Gerardy A, Deceuninck O, Xhaet O, Dormal F, Ballant E, Blommaert D, Yakova D, Hristov M, Yncheva T, Stancheva N, Tisheva S, Tokmakova M, Nikolov F, Gencheva D, Shalganov T, Kunev B, Stoyanov M, Marchov D, Gelev V, Traykov V, Kisheva A, Tsvyatkov H, Shtereva R, Bakalska-Georgieva S, Slavcheva S, Yotov Y, Kubíčková M, Marni Joensen A, Gammelmark A, Hvilsted Rasmussen L, Dinesen P, Riahi S, Krogh Venø S, Sorensen B, Korsgaard A, Andersen K, Fragtrup Hellum C, Svenningsen A, Nyvad O, Wiggers P, May O, Aarup A, Graversen B, Jensen L, Andersen M, Svejgaard M, Vester S, Hansen S, Lynggaard V, Ciudad M, Vettus R, Muda P, Maestre A, Castaño S, Cheggour S, Poulard J, Mouquet V, Leparrée S, Bouet J, Taieb J, Doucy A, Duquenne H, Furber A, Dupuis J, Rautureau J, Font M, Damiano P, Lacrimini M, Abalea J, Boismal S, Menez T, Mansourati J, Range G, Gorka H, Laure C, Vassalière C, Elbaz N, Lellouche N, Djouadi K, Roubille F, Dietz D, Davy J, Granier M, Winum P, Leperchois-Jacquey C, Kassim H, Marijon E, Le Heuzey J, Fedida J, Maupain C, Himbert C, Gandjbakhch E, Hidden-Lucet F, Duthoit G, Badenco N, Chastre T, Waintraub X, Oudihat M, Lacoste J, Stephan C, Bader H, Delarche N, Giry L, Arnaud D, Lopez C, Boury F, Brunello I, Lefèvre M, Mingam R, Haissaguerre M, Le Bidan M, Pavin D, Le Moal V, Leclercq C, Piot O, Beitar T, Martel I, Schmid A, Sadki N, Romeyer-Bouchard C, Da Costa A, Arnault I, Boyer M, Piat C, Fauchier L, Lozance N, Nastevska S, Doneva A, Fortomaroska Milevska B, Sheshoski B, Petroska K, Taneska N, Bakrecheski N, Lazarovska K, Jovevska S, Ristovski V, Antovski A, Lazarova E, Kotlar I, Taleski J, Poposka L, Kedev S, Zlatanovik N, Jordanova S, Bajraktarova Proseva T, Doncovska S, Maisuradze D, Esakia A, Sagirashvili E, Lartsuliani K, Natelashvili N, Gumberidze N, Gvenetadze R, Etsadashvili K, Gotonelia N, Kuridze N, Papiashvili G, Menabde I, Glöggler S, Napp A, Lebherz C, Romero H, Schmitz K, Berger M, Zink M, Köster S, Sachse J, Vonderhagen E, Soiron G, Mischke K, Reith R, Schneider M, Rieker W, Boscher D, Taschareck A, Beer A, Oster D, Ritter O, Adamczewski J, Walter S, Frommhold A, Luckner E, Richter J, Schellner M, Landgraf S, Bartholome S, Naumann R, Schoeler J, Westermeier D, William F, Wilhelm K, Maerkl M, Oekinghaus R, Denart M, Kriete M, Tebbe U, Scheibner T, Gruber M, Gerlach A, Beckendorf C, Anneken L, Arnold M, Lengerer S, Bal Z, Uecker C, Förtsch H, Fechner S, Mages V, Martens E, Methe H, Schmidt T, Schaeffer B, Hoffmann B, Moser J, Heitmann K, Willems S, Willems S, Klaus C, Lange I, Durak M, Esen E, Mibach F, Mibach H, Utech A, Gabelmann M, Stumm R, Ländle V, Gartner C, Goerg C, Kaul N, Messer S, Burkhardt D, Sander C, Orthen R, Kaes S, Baumer A, Dodos F, Barth A, Schaeffer G, Gaertner J, Winkler J, Fahrig A, Aring J, Wenzel I, Steiner S, Kliesch A, Kratz E, Winter K, Schneider P, Haag A, Mutscher I, Bosch R, Taggeselle J, Meixner S, Schnabel A, Shamalla A, Hötz H, Korinth A, Rheinert C, Mehltretter G, Schön B, Schön N, Starflinger A, Englmann E, Baytok G, Laschinger T, Ritscher G, Gerth A, Dechering D, Eckardt L, Kuhlmann M, Proskynitopoulos N, Brunn J, Foth K, Axthelm C, Hohensee H, Eberhard K, Turbanisch S, Hassler N, Koestler A, Stenzel G, Kschiwan D, Schwefer M, Neiner S, Hettwer S, Haeussler-Schuchardt M, Degenhardt R, Sennhenn S, Steiner S, Brendel M, Stoehr A, Widjaja W, Loehndorf S, Logemann A, Hoskamp J, Grundt J, Block M, Ulrych R, Reithmeier A, Panagopoulos V, Martignani C, Bernucci D, Fantecchi E, Diemberger I, Ziacchi M, Biffi M, Cimaglia P, Frisoni J, Boriani G, Giannini I, Boni S, Fumagalli S, Pupo S, Di Chiara A, Mirone P, Fantecchi E, Boriani G, Pesce F, Zoccali C, Malavasi VL, Mussagaliyeva A, Ahyt B, Salihova Z, Koshum-Bayeva K, Kerimkulova A, Bairamukova A, Mirrakhimov E, Lurina B, Zuzans R, Jegere S, Mintale I, Kupics K, Jubele K, Erglis A, Kalejs O, Vanhear K, Burg M, Cachia M, Abela E, Warwicker S, Tabone T, Xuereb R, Asanovic D, Drakalovic D, Vukmirovic M, Pavlovic N, Music L, Bulatovic N, Boskovic A, Uiterwaal H, Bijsterveld N, De Groot J, Neefs J, van den Berg N, Piersma F, Wilde A, Hagens V, Van Es J, Van Opstal J, Van Rennes B, Verheij H, Breukers W, Tjeerdsma G, Nijmeijer R, Wegink D, Binnema R, Said S, Erküner Ö, Philippens S, van Doorn W, Crijns H, Szili-Torok T, Bhagwandien R, Janse P, Muskens A, van Eck M, Gevers R, van der Ven N, Duygun A, Rahel B, Meeder J, Vold A, Holst Hansen C, Engset I, Atar D, Dyduch-Fejklowicz B, Koba E, Cichocka M, Sokal A, Kubicius A, Pruchniewicz E, Kowalik-Sztylc A, Czapla W, Mróz I, Kozlowski M, Pawlowski T, Tendera M, Winiarska-Filipek A, Fidyk A, Slowikowski A, Haberka M, Lachor-Broda M, Biedron M, Gasior Z, Kołodziej M, Janion M, Gorczyca-Michta I, Wozakowska-Kaplon B, Stasiak M, Jakubowski P, Ciurus T, Drozdz J, Simiera M, Zajac P, Wcislo T, Zycinski P, Kasprzak J, Olejnik A, Harc-Dyl E, Miarka J, Pasieka M, Ziemińska-Łuć M, Bujak W, Śliwiński A, Grech A, Morka J, Petrykowska K, Prasał M, Hordyński G, Feusette P, Lipski P, Wester A, Streb W, Romanek J, Woźniak P, Chlebuś M, Szafarz P, Stanik W, Zakrzewski M, Kaźmierczak J, Przybylska A, Skorek E, Błaszczyk H, Stępień M, Szabowski S, Krysiak W, Szymańska M, Karasiński J, Blicharz J, Skura M, Hałas K, Michalczyk L, Orski Z, Krzyżanowski K, Skrobowski A, Zieliński L, Tomaszewska-Kiecana M, Dłużniewski M, Kiliszek M, Peller M, Budnik M, Balsam P, Opolski G, Tymińska A, Ozierański K, Wancerz A, Borowiec A, Majos E, Dabrowski R, Szwed H, Musialik-Lydka A, Leopold-Jadczyk A, Jedrzejczyk-Patej E, Koziel M, Lenarczyk R, Mazurek M, Kalarus Z, Krzemien-Wolska K, Starosta P, Nowalany-Kozielska E, Orzechowska A, Szpot M, Staszel M, Almeida S, Pereira H, Brandão Alves L, Miranda R, Ribeiro L, Costa F, Morgado F, Carmo P, Galvao Santos P, Bernardo R, Adragão P, Ferreira da Silva G, Peres M, Alves M, Leal M, Cordeiro A, Magalhães P, Fontes P, Leão S, Delgado A, Costa A, Marmelo B, Rodrigues B, Moreira D, Santos J, Santos L, Terchet A, Darabantiu D, Mercea S, Turcin Halka V, Pop Moldovan A, Gabor A, Doka B, Catanescu G, Rus H, Oboroceanu L, Bobescu E, Popescu R, Dan A, Buzea A, Daha I, Dan G, Neuhoff I, Baluta M, Ploesteanu R, Dumitrache N, Vintila M, Daraban A, Japie C, Badila E, Tewelde H, Hostiuc M, Frunza S, Tintea E, Bartos D, Ciobanu A, Popescu I, Toma N, Gherghinescu C, Cretu D, Patrascu N, Stoicescu C, Udroiu C, Bicescu G, Vintila V, Vinereanu D, Cinteza M, Rimbas R, Grecu M, Cozma A, Boros F, Ille M, Tica O, Tor R, Corina A, Jeewooth A, Maria B, Georgiana C, Natalia C, Alin D, Dinu-Andrei D, Livia M, Daniela R, Larisa R, Umaar S, Tamara T, Ioachim Popescu M, Nistor D, Sus I, Coborosanu O, Alina-Ramona N, Dan R, Petrescu L, Ionescu G, Popescu I, Vacarescu C, Goanta E, Mangea M, Ionac A, Mornos C, Cozma D, Pescariu S, Solodovnicova E, Soldatova I, Shutova J, Tjuleneva L, Zubova T, Uskov V, Obukhov D, Rusanova G, Soldatova I, Isakova N, Odinsova S, Arhipova T, Kazakevich E, Serdechnaya E, Zavyalova O, Novikova T, Riabaia I, Zhigalov S, Drozdova E, Luchkina I, Monogarova Y, Hegya D, Rodionova L, Rodionova L, Nevzorova V, Soldatova I, Lusanova O, Arandjelovic A, Toncev D, Milanov M, Sekularac N, Zdravkovic M, Hinic S, Dimkovic S, Acimovic T, Saric J, Polovina M, Potpara T, Vujisic-Tesic B, Nedeljkovic M, Zlatar M, Asanin M, Vasic V, Popovic Z, Djikic D, Sipic M, Peric V, Dejanovic B, Milosevic N, Stevanovic A, Andric A, Pencic B, Pavlovic-Kleut M, Celic V, Pavlovic M, Petrovic M, Vuleta M, Petrovic N, Simovic S, Savovic Z, Milanov S, Davidovic G, Iric-Cupic V, Simonovic D, Stojanovic M, Stojanovic S, Mitic V, Ilic V, Petrovic D, Deljanin Ilic M, Ilic S, Stoickov V, Markovic S, Kovacevic S, García Fernandez A, Perez Cabeza A, Anguita M, Tercedor Sanchez L, Mau E, Loayssa J, Ayarra M, Carpintero M, Roldán Rabadan I, Leal M, Gil Ortega M, Tello Montoliu A, Orenes Piñero E, Manzano Fernández S, Marín F, Romero Aniorte A, Veliz Martínez A, Quintana Giner M, Ballesteros G, Palacio M, Alcalde O, García-Bolao I, Bertomeu Gonzalez V, Otero-Raviña F, García Seara J, Gonzalez Juanatey J, Dayal N, Maziarski P, Gentil-Baron P, Shah D, Koç M, Onrat E, Dural IE, Yilmaz K, Özin B, Tan Kurklu S, Atmaca Y, Canpolat U, Tokgozoglu L, Dolu AK, Demirtas B, Sahin D, Ozcan Celebi O, Diker E, Gagirci G, Turk UO, Ari H, Polat N, Toprak N, Sucu M, Akin Serdar O, Taha Alper A, Kepez A, Yuksel Y, Uzunselvi A, Yuksel S, Sahin M, Kayapinar O, Ozcan T, Kaya H, Yilmaz MB, Kutlu M, Demir M, Gibbs C, Kaminskiene S, Bryce M, Skinner A, Belcher G, Hunt J, Stancombe L, Holbrook B, Peters C, Tettersell S, Shantsila A, Lane D, Senoo K, Proietti M, Russell K, Domingos P, Hussain S, Partridge J, Haynes R, Bahadur S, Brown R, McMahon S, Y H Lip G, McDonald J, Balachandran K, Singh R, Garg S, Desai H, Davies K, Goddard W, Galasko G, Rahman I, Chua Y, Payne O, Preston S, Brennan O, Pedley L, Whiteside C, Dickinson C, Brown J, Jones K, Benham L, Brady R, Buchanan L, Ashton A, Crowther H, Fairlamb H, Thornthwaite S, Relph C, McSkeane A, Poultney U, Kelsall N, Rice P, Wilson T, Wrigley M, Kaba R, Patel T, Young E, Law J, Runnett C, Thomas H, McKie H, Fuller J, Pick S, Sharp A, Hunt A, Thorpe K, Hardman C, Cusack E, Adams L, Hough M, Keenan S, Bowring A, Watts J, Zaman J, Goffin K, Nutt H, Beerachee Y, Featherstone J, Mills C, Pearson J, Stephenson L, Grant S, Wilson A, Hawksworth C, Alam I, Robinson M, Ryan S, Egdell R, Gibson E, Holland M, Leonard D, Mishra B, Ahmad S, Randall H, Hill J, Reid L, George M, McKinley S, Brockway L, Milligan W, Sobolewska J, Muir J, Tuckis L, Winstanley L, Jacob P, Kaye S, Morby L, Jan A, Sewell T, Boos C, Wadams B, Cope C, Jefferey P, Andrews N, Getty A, Suttling A, Turner C, Hudson K, Austin R, Howe S, Iqbal R, Gandhi N, Brophy K, Mirza P, Willard E, Collins S, Ndlovu N, Subkovas E, Karthikeyan V, Waggett L, Wood A, Bolger A, Stockport J, Evans L, Harman E, Starling J, Williams L, Saul V, Sinha M, Bell L, Tudgay S, Kemp S, Brown J, Frost L, Ingram T, Loughlin A, Adams C, Adams M, Hurford F, Owen C, Miller C, Donaldson D, Tivenan H, Button H, Nasser A, Jhagra O, Stidolph B, Brown C, Livingstone C, Duffy M, Madgwick P, Roberts P, Greenwood E, Fletcher L, Beveridge M, Earles S, McKenzie D, Beacock D, Dayer M, Seddon M, Greenwell D, Luxton F, Venn F, Mills H, Rewbury J, James K, Roberts K, Tonks L, Felmeden D, Taggu W, Summerhayes A, Hughes D, Sutton J, Felmeden L, Khan M, Walker E, Norris L, O’Donohoe L, Mozid A, Dymond H, Lloyd-Jones H, Saunders G, Simmons D, Coles D, Cotterill D, Beech S, Kidd S, Wrigley B, Petkar S, Smallwood A, Jones R, Radford E, Milgate S, Metherell S, Cottam V, Buckley C, Broadley A, Wood D, Allison J, Rennie K, Balian L, Howard L, Pippard L, Board S, Pitt-Kerby T. Epidemiology and impact of frailty in patients with atrial fibrillation in Europe. Age Ageing 2022; 51:6670566. [PMID: 35997262 DOI: 10.1093/ageing/afac192] [Citation(s) in RCA: 24] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2022] [Revised: 06/08/2022] [Indexed: 12/03/2022] Open
Abstract
BACKGROUND Frailty is a medical syndrome characterised by reduced physiological reserve and increased vulnerability to stressors. Data regarding the relationship between frailty and atrial fibrillation (AF) are still inconsistent. OBJECTIVES We aim to perform a comprehensive evaluation of frailty in a large European cohort of AF patients. METHODS A 40-item frailty index (FI) was built according to the accumulation of deficits model in the AF patients enrolled in the ESC-EHRA EORP-AF General Long-Term Registry. Association of baseline characteristics, clinical management, quality of life, healthcare resources use and risk of outcomes with frailty was examined. RESULTS Among 10,177 patients [mean age (standard deviation) 69.0 (11.4) years, 4,103 (40.3%) females], 6,066 (59.6%) were pre-frail and 2,172 (21.3%) were frail, whereas only 1,939 (19.1%) were considered robust. Baseline thromboembolic and bleeding risks were independently associated with increasing FI. Frail patients with AF were less likely to be treated with oral anticoagulants (OACs) (odds ratio 0.70, 95% confidence interval 0.55-0.89), especially with non-vitamin K antagonist OACs and managed with a rhythm control strategy, compared with robust patients. Increasing frailty was associated with a higher risk for all outcomes examined, with a non-linear exponential relationship. The use of OAC was associated with a lower risk of outcomes, except in patients with very/extremely high frailty. CONCLUSIONS In this large cohort of AF patients, there was a high burden of frailty, influencing clinical management and risk of adverse outcomes. The clinical benefit of OAC is maintained in patients with high frailty, but not in very high/extremely frail ones.
Collapse
Affiliation(s)
- Marco Proietti
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.,Geriatric Unit, IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy
| | - Giulio Francesco Romiti
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Department of Translational and Precision Medicine, Sapienza - University of Rome, Italy
| | - Marco Vitolo
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.,Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy
| | - Stephanie L Harrison
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK
| | - Deirdre A Lane
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| | - Laurent Fauchier
- Service de Cardiologie, Centre Hospitalier Universitaire Trousseau, Tours, France
| | - Francisco Marin
- Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, IMIB-Arrixaca, University of Murcia, CIBER-CV, Murcia, Spain
| | - Michael Näbauer
- Department of Cardiology, Ludwig-Maximilians-University, Munich, Germany
| | - Tatjana S Potpara
- School of Medicine, University of Belgrade, Belgrade, Serbia.,Clinical Center of Serbia, Belgrade, Serbia
| | - Gheorghe-Andrei Dan
- University of Medicine, 'Carol Davila', Colentina University Hospital, Bucharest, Romania
| | - Aldo P Maggioni
- ANMCO Research Center, Heart Care Foundation, Florence, Italy
| | - Matteo Cesari
- Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.,Geriatric Unit, IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy
| | - Giuseppe Boriani
- Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy
| | - Gregory Y H Lip
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.,Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Waintraub X, Sauve R, Vedrenne G, Amet D, Gras M, Degand B, Moini C, Duthoit G, Laredo M, Badenco N, Lesaffre F, Lepillier A, Hidden Lucet F, Hermida A, Gandjbakhch E. Endocardial ablation of ventricular tachycardia ablation in arrhythmogenic right ventricular cardiomyopathy aiming epicardial late potential abolition. Europace 2022. [DOI: 10.1093/europace/euac053.382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Catheter ablation is frequently needed to treat ventricular tachycardia (VT) in ARVC patients. Ablation aiming non-inducibility (NI) and late potential (LP) abolition has been shown to be effective1. Simultaneous endo-epicardial mapping demonstrate epicardial involvement in most VT2. However epicardial fat and vicinity of coronary artery may prevent effective epicardial ablation.
Aims
(a) evaluate endocardial-only ablation guided by epicardial late-potential recording (EA-ELP) to achieve LP abolition (LPA) and NI; (b) measure ablation-index(AI) values allowing epicardial LP suppression by endocardial ablation, as a surrogate for transmurality.
Methods
From 2019 to 2021 the authors (XW, EG) evaluated EA-ELP in ARVC patients patient referred for ablation. Our ablation protocol was previously described3. Endo and epicardial voltage mapping of the right ventricle (RV) were performed in sinus rhythm using 0.5-1.5 mV threshlods for endocardial scar and 0.5-1 mV for the epicardial. All LP were manually tagged. Programmed ventricular stimulation (PVS) was performed till S4 from the RV apex and other sites, all inducible tolerated VT were mapped. Endocardial ablation was performed with an irrigated tip catheter positioned in front of epi-LP recorded by a multi-electrode catheter aiming to eliminate or delay epi-LP as a surrogate for transmurality. For each lesion fulfilling the «transmurality criteria», the AI values were recorded. Remap was performed to validate LPA and NI was tested. Patient follow-up (FU) rely on telemonitoring in ICD-carriers and holter/exercise test for the others.
Results
11 patients were enrolled (9M/2F, mean age 45 years), 9 for VT recurrence (3 redo) and 2 for de novo VT. The median ICD therapy before ablation was 5/patient (mean 1.7). The clinical VT originated from the RV outflow tract (RVOT) in 5 patients, peritricuspid (PT) in 2, RV free wall (RFW) in 4. Substrate were more extended in the epicardium compared to the endocardium: epi-LP and scar surfaces were 42.5 cm2/118 cm2 versus 24.5 cm2/25.5 cm2 for the endocardium. In one patient, additional epicardial lesion was necessary to achieve LPA. The mean ablation duration was 3377 s. Remap showed LPA in all patients and PVS was negative in all (not tested in one due to hemodynamic instability). One patient presented retrosternal hematoma after ablation with spontaneous favorable outcome. Endocardial AI values allowing epi-LP abolition were 595 for the inferior wall, 625 in the RVOT, 604 for PT and 639 for RFW. During a mean FU of 12 months (median 16.5 mths), only one patient had VT recurrence.
Conclusion
Based on this case-series, EA-ELP appeared as a safe and effective method to treat VT in ARVC. EA-ELP ablation allowed VT suppression in 91 % of patients after an mean FU of 12 mths. The RV endocardial AI needed to suppress epi-LP ranged was between 595-639 and could be used as surrogate for transmurality in ARVC.
Collapse
Affiliation(s)
- X Waintraub
- AP-HP - Hospital Pitie-Salpetriere - Institute of Cardiology, Rhythmology Department, Paris, France
| | - R Sauve
- Biosense Webster, Paris, France
| | - G Vedrenne
- Saint Joseph Hospital, Arrhythmia Unit, Paris, France
| | - D Amet
- European Hospital Georges Pompidou, Paris, France
| | - M Gras
- La Miletrie University Hospital Centre, Poitiers, France
| | - B Degand
- La Miletrie University Hospital Centre, Poitiers, France
| | - C Moini
- JACQUES CARTIER PRIVATE HOSPITAL, Massy, France
| | - G Duthoit
- AP-HP - Hospital Pitie-Salpetriere - Institute of Cardiology, Rhythmology Department, Paris, France
| | - M Laredo
- AP-HP - Hospital Pitie-Salpetriere - Institute of Cardiology, Rhythmology Department, Paris, France
| | - N Badenco
- AP-HP - Hospital Pitie-Salpetriere - Institute of Cardiology, Rhythmology Department, Paris, France
| | - F Lesaffre
- HOSPITAL ROBERT DEBRE - UNIVERSITY HOSPITAL CENTRE OF REIMS, Reims, France
| | - A Lepillier
- Centre Cardiologique du Nord (CCN), Saint Denis, France
| | - F Hidden Lucet
- AP-HP - Hospital Pitie-Salpetriere - Institute of Cardiology, Rhythmology Department, Paris, France
| | - A Hermida
- AP-HP - Hospital Pitie-Salpetriere - Institute of Cardiology, Rhythmology Department, Paris, France
| | - E Gandjbakhch
- AP-HP - Hospital Pitie-Salpetriere - Institute of Cardiology, Rhythmology Department, Paris, France
| |
Collapse
|
13
|
Ben Kilani M, Jacon P, Badenco N, Marquie C, Ollitrault P, Behar N, Khattar P, Carabelli A, Venier S, Defaye P. How to better identify patients at high risk of inappropriate shocks before S-ICD implantation: Results from a multicenter experience. Europace 2022. [DOI: 10.1093/europace/euac053.464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Introduction
Despite the recent improvements, inappropriate shocks (IAS) in patients implanted with subcutaneous implantable cardioverter-defibrillator (S-ICD) remain a challenge in "real-life" practice. The purpose of this study was to assess the preoperative predictive factors of IAS with the latest generation of S-ICD, with a particular focus on data obtained during the screening procedure.
Methods
Between January 2017 and March 2020, 300 patients implanted with Generation 3 S-ICD system for primary and secondary prevention were included in this multicentric study. Follow-up (FU) of at least 6 months and preoperative screening procedure data were mandatory for all patients.
Results
After a mean follow-up of 22.8 (±11.4) months, appropriate therapies occurred in 12.3% patients; while 26 patients (8.7%) experienced inappropriate therapies (incidence 4.9 per 100 patient-years). The total number of inappropriate shock episodes was 48; 9 patients experienced multiple episodes. Causes of IAS were: supraventricular arrhythmias (34.6%), cardiac (30.7%) and extra-cardiac noise oversensing (38.4%). In univariate analysis, availability of all 3 sensing vectors during preoperative screening significantly reduced inappropriate therapies occurrence (hazard ratio [HR], 0.32; 95% confidence interval [CI], 0.12-0.89, P=0.028). Clinical preoperative S-ICD inappropriate shocks predictors were: history of Supraventricular Tachycardia (SVT)(HR, 4.42; 95% CI, 1.45-13.47; P=0.009); overweight (BMI>25: HR, 1.93; 95% CI, 0.83-0.4.48; P=0.13); QRS duration (HR, 1.01; 95% CI, 0.1-1.03; P=0.14) and lower QRS/T wave ratio in lead I (for a threshold < 3: HR, 4.44; 95% CI, 1.88-10.48; P=0.001). By multivariate analysis, independent factors associated with IAS were: the availability of less than 3 sensing vectors during preoperative screening (p<0.05), a low QRS/T wave ratio in lead I (for a threshold <3; p<0.001), history of SVT (p<0.001) and overweight (BMI> 25; p<0.05).
Conclusion
Automatic preoperative screening data is of high interest as a predictor of IAS with a quantitative value. ECG specificities in association with other clinical factors should be taken into consideration to identify patients at high risk for IAS.
Collapse
Affiliation(s)
- M Ben Kilani
- Grenoble Alpes University Hospital, Grenoble, France
| | - P Jacon
- Grenoble Alpes University Hospital, Grenoble, France
| | - N Badenco
- Pitie Salpetriere APHP University Hospital, Paris, France
| | - C Marquie
- Lille University Hospital, Lille, France
| | | | - N Behar
- Rennes University Hospital, Rennes, France
| | - P Khattar
- Scorff Hospital - Hospital Centre of Bretagne Sud, Lorient, France
| | - A Carabelli
- Grenoble Alpes University Hospital, Grenoble, France
| | - S Venier
- Grenoble Alpes University Hospital, Grenoble, France
| | - P Defaye
- Grenoble Alpes University Hospital, Grenoble, France
| |
Collapse
|
14
|
Schiavone M, Gasperetti A, Gulletta S, Steffel J, Kaiser L, Mitacchione G, Lavalle C, Badenco N, Dello Russo A, Olivotto I, Tondo C, Kuschyk J, Biffi M, Tilz R, Forleo GB. Age-related differences and associated outcomes of S-ICD: insights from a large, european, multicenter, real-world registry. Europace 2022. [DOI: 10.1093/europace/euac053.446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Young patients often represent the most suitable candidates for an entirely subcutaenous implantable cardioverter defibrillator (S-ICD) system, since they have to face a lifetime of device therapy and they rarely have a pre-existing or concurrent pacing or cardiac resynchronization therapy (CRT) indication. Moreover, S-ICD offers lower rate and a safer management of lead and major procedure-related complications. To date, a few limited case series and experiences with S-ICD in teenagers and young adults have shown that the S-ICD system is safe and feasible in this population, with a rate of inappropriate shocks (IS) comparable to transvenous (TV) ICD, but focused analysis on a large scale are currently lacking in this setting.
Purpose
The aim of the current study was to compare the age-related differences observed in patient selection, baseline characteristics, and device long-term associated outcomes in a large real world cohort of S-ICD recipients. The primary outcome of the study was defined as the comparisons of the IS rate observed during the entirety of follow up in the teenagers/young adult vs the adult populations. Rate of complications, freedom from sustained ventricular arrhythmic events, overall and cardiovascular mortality were also assessed in the two cohorts and assessed as secondary outcomes.
Methods
All S-ICD recipients in the ELISIR project were enrolled in the current study. Patients were classified into teenagers + young adults (≤ 30 years old) vs adults (> 30 years old), depending from patient age at device implantation (Figure 1). Rates of device-related complications and IS were compared between the cohorts.
Results
A total of 1349 patients were extracted from the ELISIR project. Teenagers and young adults represented 12.4% of the registry (n=56 teenagers; n=112 young adults). Patients were followed-up for a median of 23.1 [12.6–37.9] months. Overall, 117 (8.7%) patients experienced inappropriate S-ICD shocks and 100 (7.4%) device related complications were observed, with no age-related differences. IS resulted more frequent in the teenager and young adult cohort (14.3% vs 7.9%; p=0.006). Figure 2 reports Kaplan Meier curves for the occurrence of IS. At univariate analysis, young age was associated with IS, but after correcting for differences in arrhythmic substrate, this association resulted non-significant (aHR: 1.428 [0.883–2.331]; p=0.146). The use of SMART pass algorithm was instead associated to a strong reduction in IS (aHR 0.367 [0.245–0.548]; p<0.001).
Conclusion
The use of S-ICD in teenagers/young adults resulted safe and effective. Indeed, the rate of complications between teenagers/young adults and adults was not significantly different. Although a higher rate of IS was observed in the teenagers/young adults, when accounting for differences in baseline substrate and comorbidities, young age did not result associated with an increased risk of IS.
Collapse
Affiliation(s)
- M Schiavone
- Luigi Sacco University Hospital, Milan, Italy
| | - A Gasperetti
- Johns Hopkins University School of Medicine, Baltimore, United States of America
| | | | - J Steffel
- University of Zurich, Zurich, Switzerland
| | - L Kaiser
- Asklepios Clinic St. Georg, Hamburg, Germany
| | | | - C Lavalle
- Sapienza University of Rome, Rome, Italy
| | - N Badenco
- Pitie Salpetriere APHP University Hospital, Paris, France
| | - A Dello Russo
- Marche Polytechnic University of Ancona, Ancona, Italy
| | - I Olivotto
- Careggi University Hospital, Florence, Italy
| | - C Tondo
- IRCCS Monzino Cardiology Center, Milan, Italy
| | - J Kuschyk
- University Medical Centre of Mannheim, Mannheim, Germany
| | - M Biffi
- S. Orsola-Malpighi Policlinic, Bologna, Italy
| | - R Tilz
- University of Lubeck, Luebeck, Germany
| | - GB Forleo
- Luigi Sacco University Hospital, Milan, Italy
| |
Collapse
|
15
|
Schiavone M, Gasperetti A, Vogler J, Mitacchione G, Gulletta S, Palmisano P, Breitenstein A, Laredo M, Compagnucci P, Angeletti A, Kaiser L, Hakmi S, Russo G, Ricciardi D, De Bonis S, Arosio R, Casella M, Santini L, Pignalberi C, Piro A, Lavalle C, Pisanò E, Denora M, Viecca M, Curnis A, Badenco N, Dello Russo A, Tondo C, Kuschyk J, Della Bella P, Tilz R, Biffi M, Forleo G. C9 SUBCUTANEOUS IMPLANTABLE CARDIOVERTER DEFIBRILLATOR IN PATIENTS WITH LOW BMI: REAL–WORLD DATA FROM A EUROPEAN MULTICENTER ANALYSIS. Eur Heart J Suppl 2022. [DOI: 10.1093/eurheartj/suac011.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
Background
One of the current limitations of the S–ICD is the relatively large size of the generator compared to the TV (transvenous) ICD. There is little evidence whether the size of the current S–ICD generator is associated with an elevated risk of device–related complications in patients with a low body mass index (BMI).
Purpose
Aim of this study was to compare the device–related complications and long–term outcomes in a large real world cohort of S–ICD recipients in patients with a BMI <18 kg/m2 compared to patients with a BMI >18 kg/m2.
Methods
All consecutive patients meeting current guideline indications for ICD implantation and undergoing implantation of a S–ICD device (Boston Scientific, Marlborough, Massachusetts, USA) at 21 European institutions enrolled in the extended ELISIR registry were used for the current analysis. Patients were classified into two cohorts, depending on the BMI at the time of device implantations: BMI < 18 kg/m2 versus > 18 kg/m2.
Results
Out of a total of 1497 pts, 58 pts (3.9%) had a BMI < 18 kg/m2. Patients with BMI <18 kg/m2 were younger (44.6±2.4 vs 50.8±0.4; p = 0.004) and more frequently female (58.6% vs 22.3%, p < 0.001). No differences in any of the other baseline characteristic were observed. Implantation techniques resulted comparable between the groups (rates of 2–incision technique: 87.8% vs 91.9%; p = 0.256; inter–muscular placement: 89.7% vs 83.3%; p = 0.198). Of note, the mean PRAETORIAN score at implantation of patients with BMI <18 kg/m2 was significantly lower (33.8±9.1 vs 54.1±47.3; p = 0.035), although the vast majority of patients in both cohorts qualified as at low risk of conversion failure (100% vs 91.4%; p = 0.436). Over a median follow up time of 22.4 [11.6–36.8] months, both overall device–related complications (5.2% vs 7.4%) and rates of inappropriate shocks (12.0% vs 8.8%) resulted comparable between the two groups (p = 0.517 and p = 0.385, respectively). Figure 1 reports Kaplan–Meier curves showing the combined incidence of device–related complications and inappropriate shocks in the two groups (log–rank p = 0.576).
Conclusion
No differences in device–related complications and long–term outcomes after S–ICD implantation were observed in patients with BMI <18 kg/m2 compared to the remaining recipients in a large multicentered real–world analysis.
Collapse
Affiliation(s)
- M Schiavone
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - A Gasperetti
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - J Vogler
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - G Mitacchione
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - S Gulletta
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - P Palmisano
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - A Breitenstein
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - M Laredo
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - P Compagnucci
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - A Angeletti
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - L Kaiser
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - S Hakmi
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - G Russo
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - D Ricciardi
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - S De Bonis
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - R Arosio
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - M Casella
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - L Santini
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - C Pignalberi
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - A Piro
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - C Lavalle
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - E Pisanò
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - M Denora
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - M Viecca
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - A Curnis
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - N Badenco
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - A Dello Russo
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - C Tondo
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - J Kuschyk
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - P Della Bella
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - R Tilz
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - M Biffi
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| | - G Forleo
- OSPEDALE LUIGI SACCO, MILANO; LUBECK, HERZZENTRUM LUBECK; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SAN RAFFAELE, MILANO; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE VITO FAZZI, LECCE; CAMPUS BIOMEDICO,
| |
Collapse
|
16
|
Schiavone M, Gasperetti A, Gulletta S, Vogler J, Fastenrath F, Breitenstein A, Laredo M, Mitacchione G, Palmisano P, Compagnucci P, Kaiser L, Denora M, Hakmi S, Angeletti A, De Bonis S, Picarelli F, Casella M, Steffel J, Ferro N, Guarracini F, Santini L, Pignalberi C, Piro A, Lavalle C, Russo G, Pisanò E, Viecca M, Curnis A, Badenco N, Ricciardi D, Dello Russo A, Tondo C, Kuschyk J, Della Bella P, Biffi M, Tilz R, Forleo G. P21 AGE–RELATED DIFFERENCES AND ASSOCIATED OUTCOMES OF S–ICD: INSIGHTS FROM A LARGE, EUROPEAN, MULTICENTER REGISTRY. Eur Heart J Suppl 2022. [DOI: 10.1093/eurheartj/suac012.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Background
The subcutaneous implantable cardioverter defibrillator (S–ICD) has become an alternative to transvenous ICDs (TV–ICD) in patients who do not need pacing. To date, there is little evidence directly comparing the rates of inappropriate shocks (IAS) in young vs old S–ICD recipients.
Purpose
Aim of our study was to assess differences in device–related complications and inappropriate shocks (IS) between teenagers/young adults and adult recipients of a subcutabeous implantable cardioverter defibrillator (S–ICD) device.
Methods
Two propensity–matched cohorts of teenagers + young adults (≤ 30–year–old) and adults (> 30–year–old) were retrieved from the ELISIR registry. The primary outcome was the comparison of the inappropriate shock (IAS) rate; complications, freedom from sustained ventricular arrhythmic events, overall and cardiovascular mortality were deemed secondary outcomes.
Results
A total of 1491 patients were extracted from the ELISIR project. Teenagers + young adults represented 11.0% of the entire cohort. Two propensity–matched groups of 161 patients each were used for the analysis (Figure 1); median follow–up was 23.1 [13.2–40.5] months. 15.2% patients experienced inappropriate S–ICD shocks and 9.3% device related complications were observed with no age–related differences in IAS (16.1% vs 14.3%; p = 0.642) and complication rates (9.9% vs 8.7%; p = 0.701); Figure 2 shows a survival analysis from inappropriate shocks in the teen–ager/young adult cohort (red) and in the adult cohort (blue). At univariate analysis, young age was not associated with increased rates of IAS (HR 1.204 [0.675–2.148]: p = 0.529). At multivariate analysis (Figure 3), the use of SMART pass algorithm was associated to a strong reduction in IAS (aHR 0.292 [0.161–0.525]; p < 0.001), while ARVC was associated with higher rates of IAS (aHR 2.380 [1.205–4.697]; p = 0.012).
Conclusion
In a large multicentered European registry of patients with S–ICD, 11.0% of all recipients were teenagers or young adults. The use of S–ICD in teenagers/young adults resulted safe and effective, and the rates of complications and IAS between teenagers/young adults and adults were not significantly different. The only predictor of increased IAS was a diagnosis of ARVC.
Collapse
Affiliation(s)
- M Schiavone
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - A Gasperetti
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - S Gulletta
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - J Vogler
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - F Fastenrath
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - A Breitenstein
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - M Laredo
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - G Mitacchione
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - P Palmisano
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - P Compagnucci
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - L Kaiser
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - M Denora
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - S Hakmi
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - A Angeletti
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - S De Bonis
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - F Picarelli
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - M Casella
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - J Steffel
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - N Ferro
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - F Guarracini
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - L Santini
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - C Pignalberi
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - A Piro
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - C Lavalle
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - G Russo
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - E Pisanò
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - M Viecca
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - A Curnis
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - N Badenco
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - D Ricciardi
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - A Dello Russo
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - C Tondo
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - J Kuschyk
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - P Della Bella
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - M Biffi
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - R Tilz
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| | - G Forleo
- OSPEDALE LUIGI SACCO, MILANO; OSPEDALE SAN RAFFAELE, MILANO; HERZZENTRUM LUBECK, LUBECK; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; UNIVERSITY HOSPITAL ZURICH, ZURICH; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE CARDINALE G. PANICO, TRICASE; UNIVERSITÀ POLITECNICA DELLE MARCHE, ANCONA; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; POLICLINICO S.ORSOLA–MALPIGHI, BOLOGNA
| |
Collapse
|
17
|
Schiavone M, Gasperetti A, Mitacchione G, Angeletti A, Vogler J, Laredo M, Breitenstein A, Gulletta S, Fastenrath F, Kaiser L, Compagnucci P, Palmisano P, Ricciardi D, Santini L, De Bonis S, Piro A, Pignalberi C, Pisanò E, Hakmi S, Arosio R, Casella M, Lavalle C, Badenco N, Della Bella P, Dello Russo A, Curnis A, Tondo C, Steffel J, Viecca M, Kuschyk J, Tilz R, Biffi M, Forleo G. P25 SUBCUTANEOUS–ICD IN PATIENTS WITH HEART FAILURE: RESULTS FROM A MULTICENTER, EUROPEAN ANALYSIS. Eur Heart J Suppl 2022. [DOI: 10.1093/eurheartj/suac012.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Background
Data on patients with heart failure (HF) with a subcutaneous implantable cardioverter defibrillator (S–ICD) are scarce.
Objective
Aim of this study was to assess clinical outcomes of the S–ICD in HF patients in a real–world analysis from the largest European retrospective S–ICD registry (ELISIR).
Methods
All consecutive patients undergoing S–ICD implantation at several European institutions were used for the current analysis. The population was classified into two groups: the HF (classified as HF with reduced and mid–range ejection fraction – HFrEF and HFmrEF) vs the no–HF cohort. The primary outcome of the study was the inappropriate shock (IS) rate across the two cohorts. As secondary outcomes, appropriate shocks, cardiovascular mortality and device–related complications during follow–up were assessed
Results
A total of 1409 patients from the ELISIR registry were included; HF patients represented 57.3% of the entire cohort (n = 701, 86.9% HFrEF; n = 106,13.1% HFmrEF). Over a median follow–up of approximately 2 years, a total of 133 inappropriate shocks were observed in the entire cohort, without significant differences among the two groups (9.2% vs 9.8%, p = 0.689). 133 complex ventricular arrhythmias were adequately recognized and treated, with similar rates of appropriate shocks (9.2% vs 9.8%, p = 0.689). Inappropriate and effective shocks–free survival has been represented in Figure 1 (Kaplan–Meier estimates). At multivariate analysis (Figure 2), age (HR = 0.974 [0.955–0.992], p = 0.005), LVEF (HR = 0.954 [0.926–0.984], p = 0.003), arrhythmogenic right ventricular cardiomyopathy – ARVC (HR = 3.364 [1.206–9.384], p = 0.020) and smart pass + (HR = 0.321 [0.184–0.560], p < 0.001) remained associated with inappropriate shocks. Moreover, a low number of patients (n = 76) experienced device–related complications, more frequently in the HF cohort (6.2% vs 3.8%, p = 0.031) with no significant differences regarding any specific outcome of interest: lead infection (1.1% vs 0.7%, p = 0.381), pocket infection (1.9% vs 0.8%, p = 0.107), pocket hematoma (3.2% vs 2.8%, p = 0.668).
Conclusion
The use of S–ICD in HF patients did not result in a higher rate of inappropriate shocks when compared to no–HF patients, even when stratifying for LVEF. Only age, LVEF, ARVC e Smart Pass algorithm were predictors of the primary outcome at multivariate analysis. Despite a lower overall rate of complications in the entire cohort, HF patients experienced device–related complications more frequently.
Collapse
Affiliation(s)
- M Schiavone
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - A Gasperetti
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - G Mitacchione
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - A Angeletti
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - J Vogler
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - M Laredo
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - A Breitenstein
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - S Gulletta
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - F Fastenrath
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - L Kaiser
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - P Compagnucci
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - P Palmisano
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - D Ricciardi
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - L Santini
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - S De Bonis
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - A Piro
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - C Pignalberi
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - E Pisanò
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - S Hakmi
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - R Arosio
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - M Casella
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - C Lavalle
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - N Badenco
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - P Della Bella
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - A Dello Russo
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - A Curnis
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - C Tondo
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - J Steffel
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - M Viecca
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - J Kuschyk
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - R Tilz
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - M Biffi
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| | - G Forleo
- OSPEDALE LUIGI SACCO, MILANO; JOHNS HOPKINS UNIVERSITY, BALTIMORE; SPEDALI CIVILI BRESCIA, BRESCIA; OSPEDALE SANT‘ORSOLA, BOLOGNA; UNIVERSITY HOSPITAL SCHLESWIG–HOLSTEIN, LÜBECK; HÔPITAL PITIÉ SALPÊTRIÈRE, PARIS; UNIVERSITY HOSPITAL ZURICH, ZURICH; OSPEDALE SAN RAFFAELE, MILANO; UNIVERSITY MEDICAL CENTRE MANNHEIM, MANNHEIM; ST. GEORGE KLINIK ASKLEPIOS, HAMBURG; OSPEDALE UMBERTO I–SALESI–LANCISI,
| |
Collapse
|
18
|
Gulletta S, Gasperetti A, Schiavone M, Vogler J, Fastenrath F, Breitenstein A, Laredo M, Palmisano P, Mitacchione G, Compagnucci P, Kaiser L, Hakmi S, Angeletti A, De Bonis S, Picarelli F, Arosio R, Casella M, Steffel J, Fierro N, Guarracini F, Santini L, Pignalberi C, Piro A, Lavalle C, Pisanò E, Viecca M, Curnis A, Badenco N, Ricciardi D, Russo AD, Tondo C, Kuschyk J, Bella PD, Biffi M, Forleo GB, Tilz R. Age-related differences and associated mid-term outcomes of subcutaneous implantable cardioverter defibrillators: a propensity-matched analysis from a multicenter European registry. Heart Rhythm 2022; 19:1109-1115. [DOI: 10.1016/j.hrthm.2022.02.029] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/15/2022] [Revised: 02/22/2022] [Accepted: 02/23/2022] [Indexed: 12/24/2022]
|
19
|
Desbois A, Charpentier E, Chapelon C, Bergeret S, Badenco N, Redheuil A, Cacoub P, Saadoun D. Sarcoïdose cardiaque : stratégies diagnostiques et thérapeutiques actuelles. Rev Med Interne 2022; 43:212-224. [DOI: 10.1016/j.revmed.2021.08.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2021] [Revised: 07/22/2021] [Accepted: 08/01/2021] [Indexed: 11/26/2022]
|
20
|
Pavlovic N, Chierchia GB, Velagic V, Hermida JS, Healey S, Arena G, Badenco N, Meyer C, Chen J, Iacopino S, Anselme F, Dekker L, Scazzuso F, Packer DL, de Asmundis C, Pitschner HF, Piazza FD, Kaplon RE, Kuniss M. Initial rhythm control with cryoballoon ablation vs drug therapy: Impact on quality of life and symptoms. Am Heart J 2021; 242:103-114. [PMID: 34508694 DOI: 10.1016/j.ahj.2021.08.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Accepted: 08/13/2021] [Indexed: 11/25/2022]
Abstract
BACKGROUND Cryoballoon ablation (CBA) as a first-line rhythm control strategy is superior to antiarrhythmic drugs (AADs) for preventing atrial fibrillation (AF) recurrence; the impact of first-line CBA on quality of life (QoL) and symptoms has not been well characterized. METHODS Patients aged 18 to 75 with symptomatic paroxysmal AF naïve to rhythm control therapy were randomized (1:1) to CBA (Arctic Front Advance, Medtronic) or AAD (Class I or III). Symptoms and QoL were assessed at baseline, 1, 3, 6, 9, and 12 months using the EHRA classification and Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) and SF-36v2 questionnaires. Symptomatic palpitations were evaluated via patient diary. RESULTS Overall, 107 patients were randomized to CBA and 111 to AAD; crossovers occurred in 9%. Larger improvements in the AFEQT summary, subscale and treatment satisfaction scores were observed at 12 months with CBA vs AAD (all P <0.05). At 12 months, the mean adjusted difference in the AFEQT summary score was 9.9 points higher in the CBA group (95% CI: 5.5 -14.2, P <0.001). Clinically important improvements in the SF-36 physical and mental component scores were observed at 12 months in both groups, with no significant between group differences at this timepoint. In the CBA vs AAD group, larger improvements in EHRA class were observed at 6, 9 and 12 months (P <0.05) and the incidence rate of symptomatic palpitations was lower (4.6 vs 15.2 days/year post-blanking; IRR: 0.30, P <0.001). CONCLUSIONS In patients with symptomatic AF, first-line CBA was superior to AAD for improving AF-specific QoL and symptoms. TRIAL REGISTRATION ClinicalTrials.gov number: NCT01803438.
Collapse
|
21
|
Belhassen B, Laredo M, Roudijk RW, Peretto G, Zahavi G, Sen-Chowdhry S, Badenco N, Te Riele ASJM, Sala S, Duthoit G, van Tintelen JP, Paglino G, Sellal JM, Gasperetti A, Arbelo E, Andorin A, Ninni S, Rollin A, Peichl P, Waintraub X, Bosman LP, Pierre B, Nof E, Miles C, Tfelt-Hansen J, Protonotarios A, Giustetto C, Sacher F, Hermida JS, Havranek S, Calo L, Casado-Arroyo R, Conte G, Letsas KP, Zorio E, Bermúdez-Jiménez FJ, Behr ER, Beinart R, Fauchier L, Kautzner J, Maury P, Lacroix D, Probst V, Brugada J, Duru F, Chillou CD, Bella PD, Gandjbakhch E, Hauer R, Milman A. The prevalence of left and right bundle branch block morphology ventricular tachycardia amongst patients with arrhythmogenic cardiomyopathy and sustained ventricular tachycardia: insights from the European Survey on Arrhythmogenic Cardiomyopathy. Europace 2021; 24:285-295. [PMID: 34491328 DOI: 10.1093/europace/euab190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2021] [Accepted: 07/06/2021] [Indexed: 11/12/2022] Open
Abstract
AIMS In arrhythmogenic cardiomyopathy (ACM), sustained ventricular tachycardia (VT) typically displays a left bundle branch block (LBBB) morphology while a right bundle branch block (RBBB) morphology is rare. The present study assesses the VT morphology in ACM patients with sustained VT and their clinical and genetic characteristics. METHODS AND RESULTS Twenty-six centres from 11 European countries provided information on 954 ACM patients who had ≥1 episode of sustained VT spontaneously documented during patients' clinical course. Arrhythmogenic cardiomyopathy was defined according to the 2010 Task Force Criteria, and VT morphology according to the QRS pattern in V1. Overall, 882 (92.5%) patients displayed LBBB-VT alone and 72 (7.5%) RBBB-VT [alone in 42 (4.4%) or in combination with LBBB-VT in 30 (3.1%)]. Male sex prevalence was 79.3%, 88.1%, and 56.7% in the LBBB-VT, RBBB-VT, and LBBB + RBBB-VT groups, respectively (P = 0.007). First RBBB-VT occurred 5 years after the first LBBB-VT (46.5 ± 14.4 vs 41.1 ± 15.8 years, P = 0.011). An implanted cardioverter-defibrillator was more frequently implanted in the RBBB-VT (92.9%) and the LBBB + RBBB-VT groups (90%) than in the LBBB-VT group (68.1%) (P < 0.001). Mutations in PKP2 predominated in the LBBB-VT (65.2%) and the LBBB + RBBB-VT (41.7%) groups while DSP mutations predominated in the RBBB-VT group (45.5%). By multivariable analysis, female sex was associated with LBBB + RBBB-VT (P = 0.011) while DSP mutations were associated with RBBB-VT (P < 0.001). After a median follow-up of 103 (51-185) months, death occurred in 106 (11.1%) patients with no intergroup difference (P = 0.176). CONCLUSION RBBB-VT accounts for a significant proportion of sustained VTs in ACM. Sex and type of pathogenic mutations were associated with VT type, female sex with LBBB + RBBB-VT, and DSP mutation with RBBB-VT.
Collapse
Affiliation(s)
- Bernard Belhassen
- Heart Institute, Hadassah University Hospital, Kalman Ya'Akov Man Street, 9112001, Jerusalem, Israel.,Sackler School of Medicine, Tel Aviv University, P.O. Box 39040, Tel Aviv 6997801, Israel
| | - Mikael Laredo
- Sorbonne Université, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Institut de Cardiologie, 47-83 Boulevard de l'Hôpital, 75013 Paris, France
| | - Rob W Roudijk
- Netherlands Heart Institute, Moreelsepark 1 3511 EP Utrecht, The Netherlands
| | - Giovanni Peretto
- IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132 Milano, Italy
| | - Guy Zahavi
- Sackler School of Medicine, Tel Aviv University, P.O. Box 39040, Tel Aviv 6997801, Israel.,Department of Anesthesiology, Sheba Medical Center, Tel Hashomer, 5265601, Israel
| | - Srijita Sen-Chowdhry
- Institute of Cardiovascular Science University College London, 62 Huntley St, London WC1E 6DD, UK
| | - Nicolas Badenco
- Sorbonne Université, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Institut de Cardiologie, 47-83 Boulevard de l'Hôpital, 75013 Paris, France
| | - Anneline S J M Te Riele
- Netherlands Heart Institute, Moreelsepark 1 3511 EP Utrecht, The Netherlands.,Department of Cardiology, University Medical Center, 62 Huntley St, London WC1E 6DD, The Netherlands
| | - Simone Sala
- IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132 Milano, Italy
| | - Guillaume Duthoit
- Sorbonne Université, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Institut de Cardiologie, 47-83 Boulevard de l'Hôpital, 75013 Paris, France
| | - J Peter van Tintelen
- Netherlands Heart Institute, Moreelsepark 1 3511 EP Utrecht, The Netherlands.,Department of Genetics, University Medical Center, Moreelsepark 1 3511 EP Utrecht, The Netherlands
| | - Gabriele Paglino
- IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132 Milano, Italy
| | - Jean-Marc Sellal
- Département de Cardiologie, Centre Hospitalier Universitaire de Nancy, Vandœuvre lès-Nancy, Rue du Morvan, 54500 France
| | - Alessio Gasperetti
- Department of Cardiology, University Heart Center Zurich, Hottingerstrasse 14 CH-8032 Zürich, Switzerland
| | - Elena Arbelo
- Cardiovascular Institute, Hospital Clinic and IDIBAPS, Calle Villarroel, 170 08036 Barcelona, Catalonia, Spain
| | - Antoine Andorin
- Service de Cardiologie, CHU de Nantes, Bd Jacques Monod - 44800 Saint-Herblain, Nantes, France
| | - Sandro Ninni
- Université de Lille et Institut Cœur-Poumon, CHRU, Boulevard du Professeur Jules Leclercq, 59000 Lille, France
| | - Anne Rollin
- Cardiology, University Hospital Rangueil, 1 Avenue du Professeur Jean Poulhès, 31400 Toulouse, France
| | - Petr Peichl
- Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Vídeňská 1958, 140 21 Praha 4, Prague, Czech Republic
| | - Xavier Waintraub
- Sorbonne Université, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Institut de Cardiologie, 47-83 Boulevard de l'Hôpital, 75013 Paris, France
| | - Laurens P Bosman
- Netherlands Heart Institute, Moreelsepark 1 3511 EP Utrecht, The Netherlands.,Department of Cardiology, University Medical Center, 62 Huntley St, London WC1E 6DD, The Netherlands
| | - Bertrand Pierre
- Service de Cardiologie, Centre Hospitalier Universitaire Trousseau, 2 Boulevard Tonnellé, 37000 Tours, France
| | - Eyal Nof
- Sackler School of Medicine, Tel Aviv University, P.O. Box 39040, Tel Aviv 6997801, Israel.,Leviev Heart Institute, Sheba Medical Center, 5265601 Tel Hashomer, Israel
| | - Chris Miles
- Cardiovascular Sciences and Cardiology Clinical Academic Group St. George's University Hospitals NHS Foundation Trust, Cranmer Terrace London SW17 0RE, UK
| | - Jacob Tfelt-Hansen
- The Department of Cardiology, The Heart Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen 2100, Denmark.,Department of Forensic Medicine, Faculty of Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark
| | - Alexandros Protonotarios
- Nikos Protonotarios Medical Centre, Περιφερειακός, 843 00, Naxos, Greece.,UCL Institute of Cardiovascular Science, 62 Huntley St, London WC1E 6DD, UK
| | - Carla Giustetto
- Division of Cardiology, Department of Medical Sciences, University of Torino, Città della Salute e della Scienza Hospital, Corso Bramante, 88, 10126 Torino TO, Italy
| | - Frederic Sacher
- Hôpital Cardiologique du Haut-Lévêque & Université Bordeaux, LIRYC Institute, Avenue du Haut Lévêque, 33600 Pessac, Bordeaux, France
| | - Jean-Sylvain Hermida
- Centre Hospitalier Universitaire d'Amiens-Picardie, 2 Place Victor Pauchet, 80080 Amiens, France
| | - Stepan Havranek
- Second Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Kateřinská 1660/32, 121 08 Nové Město, Prague, Czech Republic
| | - Leonardo Calo
- Division of Cardiology, Policlinico Casilino, Via Casilina, 1049, 00169 Roma RM, Italy
| | - Ruben Casado-Arroyo
- Department of Cardiology, Erasme University Hospital, Université Libre de Bruxelles, Route de Lennik 808, 1070 Bruxelles, Belgium
| | - Giulio Conte
- Electrophysiology Unit, Department of Cardiology, Fondazione Cardiocentro Ticino, Via Tesserete 48, 6900 Lugano, Switzerland
| | - Konstantinos P Letsas
- Arrhythmia Unit, Second Department of Cardiology, "Evangelismos" General Hospital of Athens, Ipsilantou 45-47, Athina 106 76, Athens, Greece
| | - Esther Zorio
- Cardiology Department at Hospital Universitario y Politecnico La Fe and Research Group on Inherited Heart Diseases, Sudden Death and Mechanisms of Disease (CaFaMuSMe) from the Instituto de Investigación Sanitaria (IIS) La Fe, Avenida Fernando Abril Martorell, Torre 106 A 7planta, Valencia, Spain.,Center for Biomedical Network Research on Cardiovascular Diseases (CIBERCV), Av. Monforte de Lemos, 3-5. Pabellón 11. Planta 0 28029, Madrid, Spain
| | - Francisco J Bermúdez-Jiménez
- Cardiology Department, Hospital Universitario Virgen de las Nieves, Av. de las Fuerzas Armadas, 2, 18014 Granada, Spain
| | - Elijah R Behr
- Cardiovascular Sciences and Cardiology Clinical Academic Group St. George's University Hospitals NHS Foundation Trust, Cranmer Terrace London SW17 0RE, UK
| | - Roy Beinart
- Sackler School of Medicine, Tel Aviv University, P.O. Box 39040, Tel Aviv 6997801, Israel.,Leviev Heart Institute, Sheba Medical Center, 5265601 Tel Hashomer, Israel
| | - Laurent Fauchier
- Service de Cardiologie, Centre Hospitalier Universitaire Trousseau, 2 Boulevard Tonnellé, 37000 Tours, France.,Université François Rabelais, 60 rue du Plat D'Etain 37020 Tours cedex 1, France
| | - Josef Kautzner
- Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Vídeňská 1958, 140 21 Praha 4, Prague, Czech Republic
| | - Philippe Maury
- Cardiology, University Hospital Rangueil, 1 Avenue du Professeur Jean Poulhès, 31400 Toulouse, France
| | - Dominique Lacroix
- Université de Lille et Institut Cœur-Poumon, CHRU, Boulevard du Professeur Jules Leclercq, 59000 Lille, France
| | - Vincent Probst
- Service de Cardiologie, CHU de Nantes, Bd Jacques Monod - 44800 Saint-Herblain, Nantes, France
| | - Josep Brugada
- Cardiovascular Institute, Hospital Clínic Pediatric Arrhythmia Unit, Hospital Sant Joan de Déu University of Barcelona, Passeig de Sant Joan de Déu, 2, 08950 Esplugues de Llobregat, Barcelona, Spain
| | - Firat Duru
- Department of Cardiology, University Heart Center Zurich, Hottingerstrasse 14 CH-8032 Zürich, Switzerland
| | - Christian de Chillou
- Département de Cardiologie, Centre Hospitalier Universitaire de Nancy, Vandœuvre lès-Nancy, Rue du Morvan, 54500 France
| | - Paolo Della Bella
- IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132 Milano, Italy
| | - Estelle Gandjbakhch
- Sorbonne Université, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Institut de Cardiologie, 47-83 Boulevard de l'Hôpital, 75013 Paris, France
| | - Richard Hauer
- Netherlands Heart Institute, Moreelsepark 1 3511 EP Utrecht, The Netherlands.,Department of Cardiology, University Medical Center, 62 Huntley St, London WC1E 6DD, The Netherlands
| | - Anat Milman
- Sackler School of Medicine, Tel Aviv University, P.O. Box 39040, Tel Aviv 6997801, Israel.,Leviev Heart Institute, Sheba Medical Center, 5265601 Tel Hashomer, Israel
| |
Collapse
|
22
|
Rolland T, Badenco N, Maupain C, Duthoit G, Waintraub X, Laredo M, Himbert C, Frank R, Hidden-Lucet F, Gandjbakhch E. Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy. Europace 2021; 24:278-284. [PMID: 34459901 DOI: 10.1093/europace/euab182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2021] [Accepted: 07/05/2021] [Indexed: 11/14/2022] Open
Abstract
AIMS Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiomyopathy associated with a high risk of ventricular arrhythmia (VA). Current guidelines recommend beta-blockers as first-line medical therapy and if ineffective, sotalol or amiodarone. We describe our experience, as a tertiary centre for ARVC, with the effectiveness and tolerance of flecainide in addition to beta-blockers to prevent VA in ARVC. METHODS AND RESULTS We retrospectively included 100 consecutive ARVC patients who received flecainide with beta-blockers between May 1999 and November 2017. Treatment persistence and related side effects were assessed, as was VA-free survival on treatment, 24-h Holter monitoring and programmed ventricular stimulation (PVS) off- and on-treatment. Tolerance was good, with 10% flecainide discontinuations (lack of efficacy in six, atrial fibrillation in one, and side effects in three). No Brugada-induced electrocardiography pattern on flecainide or haemodynamic impairment was reported. Premature ventricular contraction burden at 24-h Holter monitoring was significantly decreased under treatment [median 415 (interquartile range, IQR 97-730) vs. 2370 (1572-3400) at baseline, P < 0.0001, n = 46]. Among the 33 patients with PVS under treatment, PVS was positive in 40% on-treatment vs. 94% off-treatment (P < 0.001). During a median follow-up of 47 months (IQR 23-73), 22 patients presented sustained VA on treatment, corresponding to an event rate of 5% [95% confidence interval (CI) (0.6-9)] at 1 year and 25% [95% CI (14-35)] at 5 years under treatment. No patient died. CONCLUSION This study suggests that flecainide and beta-blockers association is complementary to implantable cardioverter-defibrillator and catheter ablation and is safe for treating persistent symptomatic VA in patients with ARVC.
Collapse
Affiliation(s)
- Thomas Rolland
- Sorbonne Universités, UPMC Univ Paris 06, Paris, France.,APHP, Pitié-Salpêtriére University Hospital, Institute of Cardiology, Paris, France.,Centre de Référence des Maladies Cardiaques Héréditaires, Paris, France.,Action Coeur Study Groupe, Paris, France.,Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
| | - Nicolas Badenco
- Sorbonne Universités, UPMC Univ Paris 06, Paris, France.,APHP, Pitié-Salpêtriére University Hospital, Institute of Cardiology, Paris, France.,Centre de Référence des Maladies Cardiaques Héréditaires, Paris, France.,Action Coeur Study Groupe, Paris, France.,Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
| | - Carole Maupain
- Sorbonne Universités, UPMC Univ Paris 06, Paris, France.,APHP, Pitié-Salpêtriére University Hospital, Institute of Cardiology, Paris, France.,Centre de Référence des Maladies Cardiaques Héréditaires, Paris, France.,Action Coeur Study Groupe, Paris, France.,Institute of Cardiometabolism and Nutrition (ICAN), Paris, France.,APHP, Pitié-Salpêtriére University Hospital, Department of Genetics, Paris, France
| | - Guillaume Duthoit
- Sorbonne Universités, UPMC Univ Paris 06, Paris, France.,APHP, Pitié-Salpêtriére University Hospital, Institute of Cardiology, Paris, France.,Centre de Référence des Maladies Cardiaques Héréditaires, Paris, France.,Action Coeur Study Groupe, Paris, France.,Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
| | - Xavier Waintraub
- Sorbonne Universités, UPMC Univ Paris 06, Paris, France.,APHP, Pitié-Salpêtriére University Hospital, Institute of Cardiology, Paris, France.,Centre de Référence des Maladies Cardiaques Héréditaires, Paris, France.,Action Coeur Study Groupe, Paris, France.,Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
| | - Mikael Laredo
- Sorbonne Universités, UPMC Univ Paris 06, Paris, France.,APHP, Pitié-Salpêtriére University Hospital, Institute of Cardiology, Paris, France.,Centre de Référence des Maladies Cardiaques Héréditaires, Paris, France.,Action Coeur Study Groupe, Paris, France.,Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
| | - Caroline Himbert
- Sorbonne Universités, UPMC Univ Paris 06, Paris, France.,APHP, Pitié-Salpêtriére University Hospital, Institute of Cardiology, Paris, France.,Centre de Référence des Maladies Cardiaques Héréditaires, Paris, France.,Action Coeur Study Groupe, Paris, France.,Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
| | - Robert Frank
- Sorbonne Universités, UPMC Univ Paris 06, Paris, France.,APHP, Pitié-Salpêtriére University Hospital, Institute of Cardiology, Paris, France.,Centre de Référence des Maladies Cardiaques Héréditaires, Paris, France.,Action Coeur Study Groupe, Paris, France.,Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
| | - Francoise Hidden-Lucet
- Sorbonne Universités, UPMC Univ Paris 06, Paris, France.,APHP, Pitié-Salpêtriére University Hospital, Institute of Cardiology, Paris, France.,Centre de Référence des Maladies Cardiaques Héréditaires, Paris, France.,Action Coeur Study Groupe, Paris, France.,Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
| | - Estelle Gandjbakhch
- Sorbonne Universités, UPMC Univ Paris 06, Paris, France.,APHP, Pitié-Salpêtriére University Hospital, Institute of Cardiology, Paris, France.,Centre de Référence des Maladies Cardiaques Héréditaires, Paris, France.,Action Coeur Study Groupe, Paris, France.,Institute of Cardiometabolism and Nutrition (ICAN), Paris, France.,APHP, Pitié-Salpêtriére University Hospital, Department of Genetics, Paris, France
| |
Collapse
|
23
|
Kuniss M, Pavlovic N, Velagic V, Hermida JS, Healey S, Arena G, Badenco N, Meyer C, Chen J, Iacopino S, Anselme F, Packer DL, Pitschner HF, Asmundis CD, Willems S, Di Piazza F, Becker D, Chierchia GB. Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation. Europace 2021; 23:1033-1041. [PMID: 33728429 PMCID: PMC8286851 DOI: 10.1093/europace/euab029] [Citation(s) in RCA: 104] [Impact Index Per Article: 34.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2020] [Accepted: 01/25/2021] [Indexed: 12/15/2022] Open
Abstract
AIMS Treatment guidelines for patients with atrial fibrillation (AF) suggest that patients should be managed with an antiarrhythmic drug (AAD) before undergoing catheter ablation (CA). This study evaluated whether pulmonary vein isolation employing cryoballoon CA is superior to AAD therapy for the prevention of atrial arrhythmia (AA) recurrence in rhythm control naive patients with paroxysmal AF (PAF). METHODS AND RESULTS A total of 218 treatment naive patients with symptomatic PAF were randomized (1 : 1) to cryoballoon CA (Arctic Front Advance, Medtronic) or AAD (Class I or III) and followed for 12 months. The primary endpoint was ≥1 episode of recurrent AA (AF, atrial flutter, or atrial tachycardia) >30 s after a prespecified 90-day blanking period. Secondary endpoints included the rate of serious adverse events (SAEs) and recurrence of symptomatic palpitations (evaluated via patient diaries). Freedom from AA was achieved in 82.2% of subjects in the cryoballoon arm and 67.6% of subjects in the AAD arm (HR = 0.48, P = 0.01). There were no group differences in the time-to-first (HR = 0.76, P = 0.28) or overall incidence [incidence rate ratio (IRR)=0.79, P = 0.28] of SAEs. The incidence rate of symptomatic palpitations was lower in the cryoballoon (7.61 days/year) compared with the AAD arm (18.96 days/year; IRR = 0.40, P < 0.001). CONCLUSIONS Cryoballoon CA was superior to AAD therapy, significantly reducing AA recurrence in treatment naive patients with PAF. Additionally, cryoballoon CA was associated with lower symptom recurrence and a similar rate of SAEs compared with AAD therapy.
Collapse
Affiliation(s)
- Malte Kuniss
- Kerckhoff Heart Center, Benekestrasse 2-8, 61231 Bad Nauheim, Germany
| | - Nikola Pavlovic
- Sestre Milosrdnice University Hospital Centre, Zagreb, Croatia
| | | | | | | | | | - Nicolas Badenco
- AP-HP Sorbonne Université, ICAN Institute, Hopital Pitié-Salpétrière, Paris, France
| | - Christian Meyer
- University Heart Center, Hamburg, Cardiac Neuro- and Electrophysiology Research Consortium, EVK Düsseldorf, Düsseldorf, Germany
| | - Jian Chen
- Haukeland University Hospital, University of Bergen, Bergen, Norway
| | | | | | | | | | - Carlo de Asmundis
- Heart Rhythm Management Centre, Universitair Ziekenhuis Brussel, Postgraduate program in Cardiac Electrophysiology and Pacing, European Reference Networks Guard-Heart, Vrije Universiteit Brussel, Brussels, Belgium
| | - Stephan Willems
- University Heart Center, Hamburg, Asklepios Klinik St. Georg, Hamburg, Germany
| | - Fabio Di Piazza
- Medtronic, Core Clinical Solutions, Study and Scientific Solutions, Rome, Italy
| | | | - Gian-Battista Chierchia
- Heart Rhythm Management Centre, Universitair Ziekenhuis Brussel, Postgraduate program in Cardiac Electrophysiology and Pacing, European Reference Networks Guard-Heart, Vrije Universiteit Brussel, Brussels, Belgium
| | | |
Collapse
|
24
|
Laredo M, Belhassen B, Peretto G, Roudijk R, Zahavi G, Sen-Chowdhry S, Badenco N, Riele AT, Sala S, Duthoit G, van Tintelen P, Paglino G, Sellal JM, Gasperetti A, Arbelo E, Andorin A, Ninni S, Rollin A, Peichl P, Waintraub X, Bosman LP, Pierre B, Nof E, Miles C, Tfelt J, Protonarios A, Giustetto C, Sacher F, Hermida JS, Havranek S, Calo L, Casado R, Conte G, Letsas K, Zorio E, Jimenez F, Behr E, Beinart R, Fauchier L, Kautzner J, Maury P, Lacroix D, Probst V, Brugada J, Duru F, de Chillou C, Della Bella P, Gandjbakhch E, Hauer RN, Milman A. B-PO01-063 LATER ONSET OF FIRST SUSTAINED RBBB-VT AS COMPARED TO FIRST LBBB-VT IN PATIENTS WITH ARRHYTHMOGENIC CARDIOMYOPATHY. Heart Rhythm 2021. [DOI: 10.1016/j.hrthm.2021.06.209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
25
|
Laredo M, Belhassen B, Roudijk R, Peretto G, Zahavi G, Sen-Chowdhry S, Badenco N, te Riele AS, Sala S, Duthoit G, van Tintelen JP, Sellal JM, Gasperetti A, Arbelo E, Andorin A, Ninni S, Rollin A, Peichl P, Waintraub X, Bosman LP, Eyal Nof, Miles C, Tflet-Hansen J, Protonarios A, Giustetto C, Sacher F, Hermida JS, Leonardo Calo SH, Casado R, Conte G, Letsas K, Zorio E, Bermúdez Jiménez FJ, Behr E, Beinart R, Fauchier L, Kautzner J, Maury P, Lacroix D, Probst V, Brugada J, Duru F, Chillou CD, Della Bella P, Gandjbakhch E, Hauer RN, Milman A. B-PO04-170 SEX DIFFERENCES IN PATIENTS WITH ARRHYTHMOGENIC CARDIOMYOPATHY WITH RESPECT TO VENTRICULAR TACHYCARDIA MORPHOLOGY. Heart Rhythm 2021. [DOI: 10.1016/j.hrthm.2021.06.862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
26
|
Forleo GB, Gasperetti A, Breitenstein A, Laredo M, Schiavone M, Ziacchi M, Vogler J, Ricciardi D, Palmisano P, Piro A, Compagnucci P, Waintraub X, Mitacchione G, Carrassa G, Russo G, De Bonis S, Angeletti A, Bisignani A, Picarelli F, Casella M, Bressi E, Rovaris G, Calò L, Santini L, Pignalberi C, Lavalle C, Viecca M, Pisanò E, Olivotto I, Curnis A, Dello Russo A, Tondo C, Love CJ, Di Biase L, Steffel J, Tilz R, Badenco N, Biffi M. Subcutaneous implantable cardioverter-defibrillator and defibrillation testing: A propensity-matched pilot study. Heart Rhythm 2021; 18:2072-2079. [PMID: 34214647 DOI: 10.1016/j.hrthm.2021.06.1201] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/10/2021] [Revised: 06/22/2021] [Accepted: 06/27/2021] [Indexed: 11/28/2022]
Abstract
BACKGROUND To date, only a few comparisons between subcutaneous implantable cardioverter-defibrillator (S-ICD) patients undergoing and those not undergoing defibrillation testing (DT) at implantation (DT+ vs DT-) have been reported. OBJECTIVE The purpose of this study was to compare long-term clinical outcomes of 2 propensity-matched cohorts of DT+ and DT- patients. METHODS Among consecutive S-ICD patients implanted across 17 centers from January 2015 to October 2020, DT- patients were 1:1 propensity-matched for baseline characteristics with DT+ patients. The primary outcome was a composite of ineffective shocks and cardiovascular mortality. Appropriate and inappropriate shock rates were deemed secondary outcomes. RESULTS Among 1290 patients, a total of 566 propensity-matched patients (283 DT+; 283 DT-) served as study population. Over median follow-up of 25.3 months, no significant differences in primary outcome event rates were found (10 DT+ vs 14 DT-; P = .404) as well as for ineffective shocks (5 DT- vs 3 DT+; P = .725). At multivariable Cox regression analysis, DT performance was associated with a reduction of neither the primary combined outcome nor ineffective shocks at follow-up. A high PRAETORIAN score was positively associated with both the primary outcome (hazard ratio 3.976; confidence interval 1.339-11.802; P = .013) and ineffective shocks alone at follow-up (hazard ratio 19.030; confidence interval 4.752-76.203; P = .003). CONCLUSION In 2 cohorts of strictly propensity-matched patients, DT performance was not associated with significant differences in cardiovascular mortality and ineffective shocks. The PRAETORIAN score is capable of correctly identifying a large percentage of patients at risk for ineffective shock conversion in both cohorts.
Collapse
Affiliation(s)
| | - Alessio Gasperetti
- Cardiology Unit, Luigi Sacco University Hospital, Milan, Italy; Cardiology and Arrhythmology Clinic, University Hospital "Umberto I-Salesi-Lancisi", Ancona, Italy; Division of Cardiology, Johns Hopkins University, Baltimore, Maryland
| | | | | | - Marco Schiavone
- Cardiology Unit, Luigi Sacco University Hospital, Milan, Italy.
| | - Matteo Ziacchi
- Cardiology Unit, Sant'Orsola Hospital, University of Bologna, Bologna, Italy
| | - Julia Vogler
- Cardiology Department, University Hospital of Lubeck, Lubeck, Germany
| | | | | | - Agostino Piro
- Cardiology Department, Policlinico Umberto I, Rome, Italy
| | - Paolo Compagnucci
- Cardiology and Arrhythmology Clinic, University Hospital "Umberto I-Salesi-Lancisi", Ancona, Italy
| | | | | | | | - Giulia Russo
- Cardiology Department, Vito Fazzi Hospital, Lecce, Italy
| | - Silvana De Bonis
- Cardiology Department, Ferrari Hospital, Castrovillari, Cosenza, Italy
| | - Andrea Angeletti
- Cardiology Unit, Sant'Orsola Hospital, University of Bologna, Bologna, Italy
| | - Antonio Bisignani
- Cardiology Department, Ferrari Hospital, Castrovillari, Cosenza, Italy
| | | | - Michela Casella
- Cardiology and Arrhythmology Clinic, University Hospital "Umberto I-Salesi-Lancisi", Ancona, Italy
| | - Edoardo Bressi
- Cardiology Department, Policlinico Casilino, Rome, Italy
| | | | - Leonardo Calò
- Cardiology Department, Policlinico Casilino, Rome, Italy
| | - Luca Santini
- Cardiology Department, Ospedale G.B. Grassi, Ostia, Italy
| | | | - Carlo Lavalle
- Cardiology Department, Policlinico Umberto I, Rome, Italy
| | - Maurizio Viecca
- Cardiology Unit, Luigi Sacco University Hospital, Milan, Italy
| | - Ennio Pisanò
- Cardiology Department, Vito Fazzi Hospital, Lecce, Italy
| | - Iacopo Olivotto
- Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy
| | - Antonio Curnis
- Cardiology Department, Spedali Civili Brescia, Brescia, Italy
| | - Antonio Dello Russo
- Cardiology and Arrhythmology Clinic, University Hospital "Umberto I-Salesi-Lancisi", Ancona, Italy
| | - Claudio Tondo
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy; Department of Clinical Electrophysiology and Cardiac Pacing, Centro Cardiologico Monzino IRCCS, Milan, Italy
| | - Charles J Love
- Division of Cardiology, Johns Hopkins University, Baltimore, Maryland
| | - Luigi Di Biase
- Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York
| | - Jan Steffel
- Cardiology Department, Zurich University Hospital, Zurich, Switzerland
| | - Roland Tilz
- Cardiology Department, University Hospital of Lubeck, Lubeck, Germany
| | | | - Mauro Biffi
- Cardiology Unit, Sant'Orsola Hospital, University of Bologna, Bologna, Italy
| |
Collapse
|
27
|
Pavlovic N, Kuniss M, Velagic V, Hermida JS, Healey S, Arena G, Badenco N, Meyer C, Chen J, Iacopino S, Anselme F, Kaplon RE, Chierchia GB. Impact of initial rhythm control with cryoballoon ablation versus drug therapy on atrial fibrillation recurrence and quality of life: results from the Cryo-FIRST study. Europace 2021. [DOI: 10.1093/europace/euab116.211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Private company. Main funding source(s): Medtronic
OnBehalf
The Cryo-FIRST Investigators
Background
Cryoballoon ablation (CBA) as a first-line rhythm control strategy is superior to antiarrhythmic drugs (AADs) for preventing atrial arrhythmia recurrence; however, the impact of first-line CBA specifically on atrial fibrillation (AF) recurrence and quality of life (QoL) has not been well characterized.
Purpose
To compare AF recurrence and QoL following first-line CBA vs. AAD therapy in patients with paroxysmal AF within the CryoFIRST trial (NCT01803438).
Methods
Patients with recurrent symptomatic paroxysmal AF who had not been administered class I or III AAD therapy for >48 hours were enrolled at 18 sites in 9 countries. Patients were randomized (1:1) to CBA or AAD treatment (Class I or III). Subjects were followed by 7-day Holter at 1, 3, 6, 9, and 12 months. Time-to-first AF recurrence outside of a 90-day blanking period was estimated by Kaplan-Meier analysis. QoL was evaluated using the Atrial Fibrillation Effect on Quality of Life (AFEQT) and 36-Item Short Form Health Survey (SF-36) v2 questionnaires.
Results
Of the 218 randomized subjects, 187 (86%) completed the 12-month follow-up. By intention-to-treat (ITT) analysis, freedom from AF after blanking was achieved in 86.6% in the CBA and 74.5% in the AAD group (p = 0.023). There was no difference in the time-to-first serious adverse event between groups. In total, 84.3% of patients in the CBA vs. 75.0% of patients in the AAD arm had a clinically important improvement (≥5 points) in the AFEQT summary score. The adjusted mean difference in the AFEQT summary score at 12 months was 9.9 points higher in the CBA group (95% CI: 5.5-14.2; P < 0.001). All AFEQT subscale scores were more favorable in the CBA vs. AAD group at 12 months. There were no significant group differences in any of the SF-36 health domain scores at 12 months in the ITT analysis. In the per-protocol analysis, clinically important and significant group differences in favor of CBA were observed at 12 months for 3 of 8 SF-36 health domain scores (physical functioning, general health and social functioning).
Conclusion
CBA is superior to AAD for preventing AF recurrence and improving AF-specific QoL in patients with paroxysmal AF. AFEQT Scores at Baseline and 12 MonthsAFEQT Score, Mean ± Standard DeviationCBAAADAdjusted Mean Difference at 12 Months (CBA vs. AAD)p-valueBaseline12 MonthsBaseline12 MonthsDaily Activities65.3 ± 25.887.8 ± 17.161.0 ± 27.976.6 ± 25.48.9 (3.2-14.6)0.002Symptoms59.9 ± 24.888.8 ± 15.658.4 ± 25.280.9 ± 22.27.1 (1.5-12.7)0.014Treatment Concern59.9 ± 23.189.8 ± 14.060.4 ± 24.577.7 ± 22.212.7 (7.9-17.5)<0.001AFEQT, Atrial Fibrillation Effect on Quality of Life questionnaire. CBA, cryoballoon ablation. AAD antiarrhythmic drug.Abstract Figure. Freedom From Atrial Fibrillation
Collapse
Affiliation(s)
- N Pavlovic
- University Hospital Sestre Milosrdnice, Zagreb, Croatia
| | - M Kuniss
- Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany
| | - V Velagic
- University Hospital Centre Zagreb, Zagreb, Croatia
| | - JS Hermida
- University Hospital of Amiens, Amiens, France
| | - S Healey
- Monash Health, Clayton, Australia
| | - G Arena
- Ospedale Apuane, Massa Carrara, Italy
| | | | - C Meyer
- University Heart Centre Hamburg, Hamburg, Germany
| | - J Chen
- Haukeland University Hospital, Bergen, Norway
| | - S Iacopino
- Maria Cecilia Hospital, Cotignola, Italy
| | | | - RE Kaplon
- Medtronic, Mounds View, United States of America
| | | |
Collapse
|
28
|
Proukhnitzky J, Maupain C, Waintraub X, Badenco N, Duthoit G, Hidden-Lucet F, Himbert C, Pousset F, Redheuil A, Hebert J, Bordet C, Fedida J, Laredo M, Fressart V, Charron P, Gandjbakhch E. Prevalence and significance of atrial tachyarrhythmias in arrhythmogenic right ventricular cardiomyopathy. Archives of Cardiovascular Diseases Supplements 2021. [DOI: 10.1016/j.acvdsp.2021.04.209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
29
|
Rolland T, Badenco N, Maupain C, Duthoit G, Waintraub X, Laredo M, Himbert C, Frank R, Hidden-Lucet F, Gandjbakhch E. Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy. Archives of Cardiovascular Diseases Supplements 2021. [DOI: 10.1016/j.acvdsp.2021.04.200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
30
|
Baudinaud P, Laredo M, Badenco N, Rouanet S, Waintraub X, Duthoit G, Hidden-Lucet F, Redheuil A, Maupain C, Gandjbakhch E. External Validation of a Risk Prediction Model for Ventricular Arrhythmias in Arrhythmogenic Right Ventricular Cardiomyopathy. Can J Cardiol 2021; 37:1263-1266. [PMID: 33675936 DOI: 10.1016/j.cjca.2021.02.018] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2020] [Revised: 02/16/2021] [Accepted: 02/25/2021] [Indexed: 11/29/2022] Open
Abstract
The new 5-year ventricular arrhythmia (VA) occurrence risk model is a major breakthrough for arrhythmia risk stratification in the challenging population of patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). In the original study, the model resulted in a 20.6% reduction in implantable cardioverter-defibrillator (ICD) placement compared with the 2015 consensus, for the same protection level. However, only internal validation was performed, limiting generalisation. We externally validated the model in a European tertiary care cohort of 128 patients with ARVC with restrictive indications for primary prevention ICD placement. Overall, 74% were men, none had VA history, and a single patient had an ICD at baseline. Median age at diagnosis was 38 years (interquartile range [IQR] 28-50). During a median follow-up of 7.8 years (IQR 6.1-9.7), 15 patients (12%) experienced VA. The model provided good discrimination, with a C-index for 5-year VA risk prediction of 0.84 (95% confidence interval 0.74-0.93). However, the model led to an overestimation of the 5-year VA risk when applying thresholds < 50%. With a < 10% predicted risk, no patient showed VA. With a 7.5% predicted risk, the ICD:VA ratio was 6.3 vs 3.4 in the original study. The model still outperformed the 2015 International Task Force Consensus. Overall, in a relatively large European ARVC cohort with restrictive indications for ICD placement, the ARVC model for VA prediction successfully identified ARVC patients with VA during follow-up. Yet, our study underscores the need for careful threshold selection, considering the model's associated risk overestimation in low- to intermediate-risk patients.
Collapse
Affiliation(s)
- Pierre Baudinaud
- Institut de Cardiologie, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
| | - Mikael Laredo
- Institut de Cardiologie, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
| | - Nicolas Badenco
- Institut de Cardiologie, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
| | - Stéphanie Rouanet
- Institut de Cardiologie, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
| | - Xavier Waintraub
- Institut de Cardiologie, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
| | - Guillaume Duthoit
- Institut de Cardiologie, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
| | - Francoise Hidden-Lucet
- Institut de Cardiologie, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
| | - Alban Redheuil
- Institut de Cardiologie, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
| | - Carole Maupain
- Institut de Cardiologie, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
| | - Estelle Gandjbakhch
- Institut de Cardiologie, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
| |
Collapse
|
31
|
Chierchia G, Pavlovic N, Velagic V, Hermida J, Healy S, Arena G, Badenco N, Meyer C, Chen J, Iacopino S, Anselme F, Kuniss M. Quality of life measured in first-line therapy during the Cryo-FIRST study: a comparison between cryoballoon catheter ablation versus antiarrhythmic drug therapy. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0436] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
By consensus statements, catheter ablation is a recommended treatment for patients with symptomatic drug-refractory paroxysmal atrial fibrillation (AF), as patients try to alleviate the burdensome AF symptoms that reduce the Quality of Life (QoL). Yet, first-line treatment of symptomatic patients via catheter ablation prior to initiation of antiarrhythmic drugs (AADs) is only a reasonable alternative (Class IIa). Clearly, more clinical data is necessary that compares catheter ablation to AAD therapy in treatment naïve patients.
Purpose
The Cryo-FIRST trial was designed to compare AAD treatment against pulmonary vein isolation (PVI) while using a cryoballoon catheter (Arctic Front Advance; Medtronic, Inc.). This current data analysis examines the QoL endpoints when comparing AADs to cryoballoon ablation in patients with symptomatic treatment naïve paroxysmal AF.
Methods
This randomized multicenter trial enrolled 220 patients from 18 sites in 9 countries (Europe, Australia, and Latin America) in a prospective open-blinded endpoint study design. Patients had not been administered a class I or III AAD for longer than 48 hours for inclusion into the study. Subjects were randomized (1:1) into a cohort that was administered AAD therapy or a cohort that received PVI via cryoablation. The prespecified QoL endpoint at 12 months was measured using the Atrial Fibrillation Effect on Quality of Life (AFEQT) scores, and QoL recordings were taken at baseline, 1, 3, 6, 9, and 12 months following the index treatment.
Results
Of the 218 patients randomized (age 52±13 years, 68% male) 86% completed the 12-month follow-up. Crossovers occurred in 9% of subjects (N=20), including: 1 subject in the cryoablation arm and 19 subjects in the AAD arm. At 12 months, 86.5% of the patients in the cryoablation arm and 70.4% of the patients in the AAD arm where without symptoms (EHRA score 1). The mean AFEQT summary score was more favorable in the catheter ablation group compared to the drug therapy group at 12 months (88.9 vs. 78.1 points, respectively). The adjusted difference was 9.9 points (95% CI: 5.5–14.2; P<0.0001).
Conclusions
Cryoballoon ablation resulted in a significant improvement in QoL at 12 months compared to AAD therapy in treatment naïve patients with first-line symptomatic paroxysmal AF.
Funding Acknowledgement
Type of funding source: Private company. Main funding source(s): Medtronic International Trading Sàrl
Collapse
Affiliation(s)
- G.B Chierchia
- Vrije Universiteit Brussel, Postgraduate Course in Clinical ElectroPhysiology and Pacing, Heart Rhythm Management Center, Brussel, Belgium
| | - N Pavlovic
- Sestre Milosrdnice University Hospital Centre, Cardiology, Zagreb, Croatia
| | - V Velagic
- University Hospital Centre Zagreb, Cardiovascular Medicine, Zagreb, Croatia
| | - J.S Hermida
- Centre Hospitalier Universitaire d'Amiens-Picardie, Service de Cardiologie Rythmologie et Stimulation Cardiaque, Amiens, France
| | - S Healy
- Monash Health, MonashHeart, Clayton, Australia
| | - G Arena
- Ospedale Apuane, Cardiology, Massa Carrara, Italy
| | - N Badenco
- AP-HP Sorbonne Université, Hopital Pitié-Salpétrière, Cardiologie, Paris, France
| | - C Meyer
- University Heart Center, Department of Cardiology-Electrophysiology, Hamburg, Germany
| | - J Chen
- Haukeland University Hospital, Department of Heart Disease, Bergen, Norway
| | - S Iacopino
- Villa Maria Cecilia, Aritmologia, Cotignola, Italy
| | - F Anselme
- CHU de Rouen, Cardiologie, Rouen, France
| | - M Kuniss
- Kerckhoff Heart Center, Cardiology, Bad Nauheim, Germany
| |
Collapse
|
32
|
Proukhnitzky J, Badenco N, Gandjbakhch E, Maupain C, Waintraub X, Duthoit G, Hidden-Lucet F, Marijon E. P1480French experience of SICD implantation. Europace 2020. [DOI: 10.1093/europace/euaa162.385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
OnBehalf
GPUR
Introduction
The subcutaneous ICD prevents complications of transvenous leads. Its implantation needs a defibrillation test. Performing this test increases the time of procedures..
Purpose
The aim of our study is to describe the experience of subcutaneous ICD of Assitance Publique des Hopitaux de Paris (AP-HP).
Materials and Methods
In a retrospective cohort we included patients who were involved in subcutaneous ICD treatment at the 5 hospitals of AP-HP from December 2012 to April 2018.Analysis used the Kaplan-Meier method and the Mann-Whitney U test.
Results
162 patients were implanted. 76% of implantations were for secondary prevention before 2017, but only 49% after 2017. 126 (77%) tests were successful at first shock, 14 (8.6%) needed a second shock or more, 9 (5.5%) did not have a test. The shock impedance was significantly higher when the shock was not effective at the first test, 82 ohms CI 95% [68; 112] versus 66 ohms CI 95% [64; 70], p <0.05. 6 patients died (3.7%). Late follow up showed 23 (10%) appropriate shocks and 24 inappropriate shocks (11%) mainly due to T wave oversensing (37.5%).
Conclusions
This is the first french experience of SICD implantation. Success of defibrillation test was lower than expected.
Caracteristics of implantation General anesthesia (%) 162 (100) Procedure time (min) Mean ± SD (median)Range 73± 24 (60)20-165 Cameron Health (%) Generator SQ-RX ® 1010 12 (7.4) Boston Scientific (%) Generator EMBLEM ® A209 100 (61.7) Generator EMBLEM ® A219 44 (27.2) VF time (sec) Mean ± SD (median)Range 16.5± 3.4(15)10-37 Shock Impedance (ohm) Mean ± SD (median) Range 72 ± 12.7 (68) 42-130 Success at 1st shock (%) 126 (77.7) Success at 2nd shock or more (%) 14 (8.6) No test performed (%) 12 (7.4) Implantation caracteristics and defibrillation testing. Impedance was significantly higher in patients without success at first shock : 82 ohms CI 95% [68 ;112] vs 66 ohms CI 95% [64 ;70], p < 0.05.
Abstract Figure. Survival without inappropriate shock
Collapse
Affiliation(s)
| | - N Badenco
- Hopital La Pitie Salpetriere, Paris, France
| | | | - C Maupain
- Hopital La Pitie Salpetriere, Paris, France
| | | | - G Duthoit
- Hopital La Pitie Salpetriere, Paris, France
| | | | - E Marijon
- Hopital Europeen Georges Pompidou- University Paris Descartes, Rhythmology, Paris, France
| |
Collapse
|
33
|
Stabile G, Lepillier A, De Ruvo E, Scaglione M, Anselmino M, Sebag F, Pecora D, Gallagher M, Rillo M, Viola G, Rossi L, De Santis V, Landolina M, Castro A, Grimaldi M, Badenco N, Del Greco M, De Simone A, Pisanò E, Abbey S, Lamberti F, Pani A, Zucchelli G, Sgarito G, Dugo D, Bertaglia E, Strisciuglio T, Solimene F. Reproducibility of pulmonary vein isolation guided by the ablation index: 1-year outcome of the AIR registry. J Cardiovasc Electrophysiol 2020; 31:1694-1701. [PMID: 32369225 DOI: 10.1111/jce.14531] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Revised: 04/28/2020] [Accepted: 04/30/2020] [Indexed: 12/13/2022]
Abstract
BACKGROUND Ablation index (AI) is a new lesion quality marker that has been demonstrated to allow a high single-procedure arrhythmia-free survival in single-center studies. This prospective, multi-center study was designed to evaluate the reproducibility of pulmonary vein (PV) isolation guided by the AI. METHODS A total of 490 consecutive patients with paroxysmal (80.4%) and persistent AF underwent first time PV isolation and were divided in four study groups according to operator's preference in choosing the ablation catheter (a contact force (ST) or contact force surround flow (STSF) catheter) and the AI setting (330-450 or 380-500 at anterior wall or posterior wall, respectively). RESULTS At 12 months a high rate of freedom from AF recurrences was observed in patients with both paroxysmal and persistent AF (91% vs 83.3%; P = .039). There was no difference in the rate of AF recurrence among the four study groups (4.5% in group ST330-450, 12.2% in group ST 380-500, 14.9% in group STSF330-450, 9.4% in group STSF380-500; P = .083). Recurrence was also similar between patients treated with a ST (8%) or STSF catheter (12.1%; P = .2), and within patients targeting an AI settings of 330 to 450 (10.9%) or 380 to 500 (10.3%; P = .64). In patients with paroxysmal AF, there was no difference (P = .12) in the 1-year freedom from AF recurrence among 14 operators that performed ≥10 ablation procedure. CONCLUSIONS An ablation protocol respecting strict criteria for contiguity and quality lesion resulted in high rate of 1-year freedom from AF recurrence, irrespective of the ablation catheters, AI settings, and operator.
Collapse
Affiliation(s)
- Giuseppe Stabile
- Clinica Montevergine, Mercogliano, Avellino, Italy.,Clinica San Michele, Maddaloni, Caserta, Italy.,Anthea Hospital, Bari, Italy
| | | | | | | | - Matteo Anselmino
- Department of Medical Sciences, A. O. U. Citta della Salute e della Scienza di Torino, University of Turin, Italy
| | | | | | | | | | | | - Luca Rossi
- Ospedale Civili Guglielmo da Saliceto, Piacenza, Italy
| | | | | | | | - Massimo Grimaldi
- Ospedale Regionale Miulli, Acquaviva delle Fonti, Metropolitan City of Bari, Italy
| | | | | | | | | | - Salim Abbey
- Hôpital Privé Du Confluent (HPCN), Nantes, France
| | | | | | | | | | - Daniela Dugo
- AUO Policlinico Vittorio Emanuele, Catania, Italy
| | - Emanuele Bertaglia
- Department of Cardiac, Thoracic, and Vascular Sciences, University of Padova, Padua, Italy
| | - Teresa Strisciuglio
- Clinica Montevergine, Mercogliano, Avellino, Italy.,Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy
| | | |
Collapse
|
34
|
D’alessandro C, Badenco N, Duthoit G, Gandjbakhch E, Waintraub X, Laali M, Hidden-Lucet F, Leprince P. Totally thoracoscopic surgical versus hybrid ablation of stand alone atrial fibrillation. Archives of Cardiovascular Diseases Supplements 2020. [DOI: 10.1016/j.acvdsp.2019.09.244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
35
|
Laredo M, Oliveira Da Silva L, Extramiana F, Lellouche N, Varlet É, Amet D, Algalarrondo V, Waintraub X, Duthoit G, Badenco N, Maupain C, Hidden-Lucet F, Maury P, Gandjbakhch E. Catheter ablation of electrical storm in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm 2020; 17:41-48. [DOI: 10.1016/j.hrthm.2019.06.022] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/13/2019] [Indexed: 10/26/2022]
|
36
|
Probst V, Clerici G, Babuty D, Badenco N, Marquie C, Leenhardt A, Maury P, Blangy H, Deharo JC, Tfelt-Hansen J, Rudic B, Behar N, Mansourati J, Sacher F, Gourraud JB. P2279First clinical evaluation of subcutaneous implantable cardiac defibrillator in Brugada patients. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0756] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Brugada syndrome (BrS) is an inherited arrhythmia syndrome with an increased risk of SCD. While Subcutaneous ICD (S-ICD) is a seductive approach to treat these patients, questions raised on the risk of inappropriate shock in this specific population.
Objective
The aim of this study was to evaluate the safety and the effectiveness of the S-ICD in BrS patients.
Methods
We prospectively enrolled 112 BrS patients implanted with S-ICD in 17 European centers. During the screening at least 2 vectors must be suitable but it was not necessary to check for the suitability of the ECG during sodium channel blocker or exercise test. S-ICD indications follow the current guidelines.
Results
Mean age of patients was 45±13 years, with 95 (85%) males. Implantation was performed in 91 (83%) patients for primary prevention and in 18 (16%) patients for secondary prevention. There is an indication of ICD replacement for 16 patients (14%): 13 lead defect (81%), 1 infection (6%) and 2 ICD end of life (13%). In this cohort, 57 patients (51%) had spontaneous type I BrS, 60 patients (55%) were symptomatic: 10 resuscitated SCD (17%) and 48 (83%) syncope.
Implantation was performed under general anesthesia in 79 patients (71%). The mean operation time was 56±19 min. The lead was placed at the left side of the sternum in 102 patients (92%) and at the right side in 9 (8%). Sensing configuration was the primary vector for 46 patients (41%), secondary vector for 57 (51%) and alternative vector for 9 (8%). No complications occurred during implantation.
During a mean follow-up of 15.6 months (0–39 months), 6 patients (5%) had at least one appropriate shock (n=9). The rate of appropriate shock was 4.5%/y. All the VF episodes were successfully treated with the first shock. One patient had VF ablation for recurrent VF. Among the 6 patients who received an appropriate shock, 3 (50%) were implanted for secondary prevention and 3 (50%) were implanted for primary prevention including 2 patients with a history of syncope and one asymptomatic patient.
Twelve patients (11%) had at least one inappropriate shock (n=22) including 2 patients with respectively 8 and 4 inappropriate shocks due to T-wave oversensing. With the SMART pass system the first patient had no more inappropriate shock for now 2 years. The rate of inappropriate shock was 9%/y. One patient died of myocardial infarction.
Five patients (4%) were hospitalized for complications (4 pocket or scar infections and 1 electrode failure).
Conclusion
Our initial experience showed that S-ICD is efficient to treat VF episode in BrS patients. In this population, the rate of inappropriate shock was 9%/y. In view of these results, S-ICD implantation seems to be efficient to protect BrS patients against SCD.
Acknowledgement/Funding
Investigator-Sponsored Research program, Boston Scientific
Collapse
Affiliation(s)
- V Probst
- University Hospital of Nantes - Hospital Guillaume & Rene Laennec, Nantes, France
| | - G Clerici
- Reunion Regional University Hospital, Saint Pierre, Réunion
| | - D Babuty
- University Hospital of Tours, Tours, France
| | - N Badenco
- Hospital Pitie-Salpetriere, Paris, France
| | | | - A Leenhardt
- Hospital Bichat-Claude Bernard, Paris, France
| | - P Maury
- University Hospital of Toulouse, Toulouse, France
| | - H Blangy
- University Hospital of Nancy, Nancy, France
| | - J C Deharo
- Hospital La Timone of Marseille, Marseille, France
| | - J Tfelt-Hansen
- Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
| | - B Rudic
- University Medical Centre of Mannheim, Mannheim, Germany
| | - N Behar
- University Hospital of Rennes, Rennes, France
| | | | - F Sacher
- University Hospital of Bordeaux - Hospital Haut Leveque, Departement of Cardiology, Bordeaux-Pessac, France
| | - J B Gourraud
- University Hospital of Nantes - Hospital Guillaume & Rene Laennec, Nantes, France
| |
Collapse
|
37
|
Solimene F, Lepillier A, Ruvo E, Scaglione M, Anselmino M, Sebag FA, Pecora D, Gallagher MM, Rillo M, Viola G, Rossi L, Santis V, Landolina M, Castro A, Grimaldi M, Badenco N, Del Greco M, Simone A, Bertaglia E, Stabile G. Reproducibility of acute pulmonary vein isolation guided by the ablation index. Pacing Clin Electrophysiol 2019; 42:874-881. [DOI: 10.1111/pace.13710] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/16/2019] [Revised: 04/16/2019] [Accepted: 04/27/2019] [Indexed: 10/26/2022]
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Luca Rossi
- Ospedale Civili Guglielmo da Saliceto Piacenza Italy
| | | | | | | | | | | | | | | | - Emanuele Bertaglia
- Department of Cardiac, Thoracic, and Vascular SciencesUniversity of Padova Italy
| | - Giuseppe Stabile
- Clinica Montevergine Mercogliano (AV) Italy
- Clinica San Michele Maddaloni (CE) Italy
| |
Collapse
|
38
|
Milhem A, Ingrand P, Tréguer F, Cesari O, Da Costa A, Pavin D, Rivat P, Badenco N, Abbey S, Zannad N, Winum PF, Mansourati J, Maury P, Bader H, Savouré A, Sacher F, Andronache M, Allix-Béguec C, De Chillou C, Anselme F, Al Arnaout A, Amara W, Amelot M, Bars C, Becoulet L, Bru P, Chevalier P, Darmon JP, Deharo JC, Dompnier A, Duplantier-Duchene C, Extramiana F, Faugier JP, Guenancia C, Horvilleur J, Jourda F, Laurent G, Lellouche N, Magnin Poull I, Piot O, Roux A, Saludas Y, Seitz J, Taieb J. Exclusion of Intra-Atrial Thrombus Diagnosis Using D-Dimer Assay Before Catheter Ablation of Atrial Fibrillation. JACC Clin Electrophysiol 2019; 5:223-230. [DOI: 10.1016/j.jacep.2018.09.009] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2018] [Revised: 08/20/2018] [Accepted: 09/11/2018] [Indexed: 11/25/2022]
|
39
|
Fedida J, Badenco N, Gandjbakhch E, Waintraub X, Hidden-Lucet F, Duthoit G. Reversible mechanical atrioventricular block during cryoablation for paroxysmal atrial fibrillation with a 28 mm balloon. HeartRhythm Case Rep 2019; 5:15-16. [PMID: 30693198 PMCID: PMC6342332 DOI: 10.1016/j.hrcr.2018.09.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Affiliation(s)
- Joël Fedida
- Institut de Cardiologie, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
- UPMC Univ Paris 06, Sorbonne Universités, Paris, France
- Address reprint requests and correspondence: Dr Joël Fedida, Département de Cardiologie, AP-HP, Hôpital Pitié-Salpêtrière, 47-83 bld de l’Hôpital, 75013, Paris, France.
| | - Nicolas Badenco
- Institut de Cardiologie, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
| | - Estelle Gandjbakhch
- Institut de Cardiologie, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
- UPMC Univ Paris 06, Sorbonne Universités, Paris, France
| | - Xavier Waintraub
- Institut de Cardiologie, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
| | | | - Guillaume Duthoit
- Institut de Cardiologie, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
| |
Collapse
|
40
|
Laredo M, Oliveira L, Waintraub X, Duthoit G, Badenco N, Maupain C, Extramiana F, Lellouche N, Marijon E, Algalarrondo V, Hidden-Lucet F, Maury P, Gandjbakhch E. Outcomes after catheter ablation for treatment of electrical storm in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Archives of Cardiovascular Diseases Supplements 2019. [DOI: 10.1016/j.acvdsp.2018.10.178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
41
|
Fedida J, Waintraub X, Duthoit G, Badenco N, Chastre T, Maupain C, Himbert C, Frank R, Pavie A, Varnous S, Hidden-Lucet F, Le Prince P, Gandjbakhch E. Contribution of electrophysiogical study for syncope in heart transplant patient: Retrospective analysis of 9 cases. Archives of Cardiovascular Diseases Supplements 2019. [DOI: 10.1016/j.acvdsp.2018.10.205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
42
|
Probst V, Clerici G, Babuty D, Badenco N, Marquie C, Leenhardt A, Maury P, Blangy H, Deharo JL, Tfelt-Hansen J, Rudic B, Behar N, Mansourati J, Sacher F, Gourraud JB. 3298First clinical evaluation of subcutaneous implantable cardiac defibrillator in brugada patients. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.3298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- V Probst
- University Hospital of Nantes - Hospital Guillaume & Rene Laennec, Nantes, France
| | - G Clerici
- Reunion Regional University Hospital, Saint Pierre, Reunion
| | - D Babuty
- University Hospital of Tours, Tours, France
| | - N Badenco
- Hospital Pitie-Salpetriere, Paris, France
| | - C Marquie
- Lille University Hospital, Lille, France
| | - A Leenhardt
- Hospital Bichat-Claude Bernard, Paris, France
| | - P Maury
- University Hospital of Toulouse, Toulouse, France
| | - H Blangy
- University Hospital of Nancy, Nancy, France
| | - J L Deharo
- Hospital La Timone of Marseille, Marseille, France
| | - J Tfelt-Hansen
- Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
| | - B Rudic
- University Medical Centre of Mannheim, Mannheim, Germany
| | - N Behar
- University Hospital of Rennes, Rennes, France
| | | | - F Sacher
- University Hospital of Bordeaux - Hospital Haut Leveque, Departement of Cardiology, Bordeaux-Pessac, France
| | - J B Gourraud
- University Hospital of Nantes - Hospital Guillaume & Rene Laennec, Nantes, France
| |
Collapse
|
43
|
Laredo M, Oliveira Da Silva L, Waintraub X, Duthoit G, Badenco N, Maupain C, Extramiana F, Lellouche N, Marijon E, Algalarrondo V, Hidden-Lucet F, Maury P, Gandjbakhch E. 2116Outcomes after catheter ablation for treatment of electrical storm in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.2116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- M Laredo
- Hospital Pitie-Salpetriere, Institut de Cardiologie, Paris, France
| | - L Oliveira Da Silva
- University Hospital of Martinique, Department of Cardiology, Pointe-à-Pitre, Martinique, France
| | - X Waintraub
- Hospital Pitie-Salpetriere, Institut de Cardiologie, Paris, France
| | - G Duthoit
- Hospital Pitie-Salpetriere, Institut de Cardiologie, Paris, France
| | - N Badenco
- Hospital Pitie-Salpetriere, Institut de Cardiologie, Paris, France
| | - C Maupain
- Hospital Pitie-Salpetriere, Institut de Cardiologie, Paris, France
| | - F Extramiana
- Hospital Bichat-Claude Bernard, Department of Cardiology, Paris, France
| | - N Lellouche
- University Hospital Henri Mondor, Department of Cardiology, Creteil, France
| | - E Marijon
- Georges Pompidou European Hospital, Department of Cardiology, Paris, France
| | - V Algalarrondo
- Bicetre University Hospital, Department of Cardiology, Le Kremlin-Bicetre, France
| | - F Hidden-Lucet
- Hospital Pitie-Salpetriere, Institut de Cardiologie, Paris, France
| | - P Maury
- Toulouse Rangueil University Hospital (CHU), Division of Cardiology, Toulouse, France
| | - E Gandjbakhch
- Hospital Pitie-Salpetriere, Institut de Cardiologie, Paris, France
| |
Collapse
|
44
|
Maupain C, Badenco N, Pousset F, Waintraub X, Duthoit G, Chastre T, Himbert C, Hébert JL, Frank R, Hidden-Lucet F, Gandjbakhch E. Risk Stratification in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia Without an Implantable Cardioverter-Defibrillator. JACC Clin Electrophysiol 2018; 4:757-768. [DOI: 10.1016/j.jacep.2018.04.017] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2018] [Revised: 03/19/2018] [Accepted: 04/26/2018] [Indexed: 11/28/2022]
|
45
|
Takahashi M, Badenco N, Monteau J, Gandjbakhch E, Extramiana F, Urena M, Karam N, Marijon E, Algalarrondo V, Teiger E, Lellouche N. Impact of pacemaker mode in patients with atrioventricular conduction disturbance after trans‐catheter aortic valve implantation. Catheter Cardiovasc Interv 2018. [DOI: 10.1002/ccd.27594] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Masao Takahashi
- University Hospital Henri Mondor, Department of Cardiology, 51 Avenue du Maréchal de Lattre de TassignyCréteil94000 France
| | - Nicolas Badenco
- University Hospital Pitié‐Salpetrière, Cardiology Unit, 47‐83 bd de l'hôpitalParis75013 France
| | - Jacques Monteau
- University Hospital Henri Mondor, Department of Cardiology, 51 Avenue du Maréchal de Lattre de TassignyCréteil94000 France
| | - Estelle Gandjbakhch
- University Hospital Pitié‐Salpetrière, Cardiology Unit, 47‐83 bd de l'hôpitalParis75013 France
| | - Fabrice Extramiana
- University Hospital Bichat, Cardiology Unit, 46 Rue Henri HuchardParis75018 France
| | - Marina Urena
- University Hospital Bichat, Cardiology Unit, 46 Rue Henri HuchardParis75018 France
| | - Nicole Karam
- Cardiology DepartmentEuropean Hospital Georges Pompidou, 20 Rue LeblancParis75015 France
| | - Eloi Marijon
- Cardiology DepartmentEuropean Hospital Georges Pompidou, 20 Rue LeblancParis75015 France
| | - Vincent Algalarrondo
- University Hospital Antoine‐Béclère, Cardiology Unit, 157 Rue de la Porte de TrivauxClamart92140 France
| | - Emmanuel Teiger
- University Hospital Henri Mondor, Department of Cardiology, 51 Avenue du Maréchal de Lattre de TassignyCréteil94000 France
| | - Nicolas Lellouche
- University Hospital Henri Mondor, Department of Cardiology, 51 Avenue du Maréchal de Lattre de TassignyCréteil94000 France
| |
Collapse
|
46
|
Larnier L, Badenco N, Thuillot M, Bravetti M, Gandjbakhch E, Duthoit G. Comparison of incidences of pulmonary vein stenosis between radiofrequency and cryoablation in atrial fibrillation ablation. Archives of Cardiovascular Diseases Supplements 2018. [DOI: 10.1016/j.acvdsp.2017.11.241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
47
|
D’alessandro C, Badenco N, Duthoit G, Gandjbakhch E, Maupain C, Lebreton G, Hidden-Lucet F, Leprince P. Totally thoracoscopic surgical ablation of stand alone atrial fibrillation and concomitant left appendage exclusion. Archives of Cardiovascular Diseases Supplements 2018. [DOI: 10.1016/j.acvdsp.2017.11.251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
48
|
Fedida J, Waintraub X, Duthoit G, Varnous S, Maupain C, Badenco N, Himbert C, Frank R, Chastre T, Dagher-Hayeck Y, Golmard JL, Pavie A, Hidden-Lucet F, Leprince P, Gandjbakhch E. P257Heart transplant patients with pacemaker: predictive factors for pacemaker requirement, for type of bradyarrhythmias, and prognostic factors for survival. Europace 2017. [DOI: 10.1093/ehjci/eux171.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
49
|
Badenco N, Chong-Nguyen C, Maupain C, Himbert C, Duthoit G, Waintraub X, Chastre T, Gandjbakhch E, Hidden-Lucet F, Le Prince P, Collet JP, Frank R. Respective role of surface electrocardiogram and His bundle recordings to assess the risk of atrioventricular block after transcatheter aortic valve replacement. Int J Cardiol 2017; 236:216-220. [DOI: 10.1016/j.ijcard.2017.02.029] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/26/2016] [Revised: 01/11/2017] [Accepted: 02/06/2017] [Indexed: 11/16/2022]
|
50
|
Gandjbakhch E, Rovani M, Varnous S, Maupain C, Chastre T, Waintraub X, Pousset F, Lebreton G, Duthoit G, Badenco N, Himbert C, Leprince P, Hidden-Lucet F. Implantable cardioverter-defibrillators in end-stage heart failure patients listed for heart transplantation: Results from a large retrospective registry. Arch Cardiovasc Dis 2016; 109:476-85. [DOI: 10.1016/j.acvd.2016.02.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/13/2015] [Revised: 12/17/2015] [Accepted: 02/09/2016] [Indexed: 11/17/2022]
|